Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 24th, 2026

LECO_Weekly-Healthcare-News_8-24-2026Download

Healthcare Weekly News and Deals

  1. Francisco Partners to take Weave Communications (NYSE: WEAV) private for $650 million in an all-cash deal at $7.40 per share. The price is a 34% premium to Weave’s Monday closing price, and the company will delist after going public in 2021. The sponsor is buying a vertical platform serving independent medical, dental, optometry and veterinary practices, a customer base most software companies overlook. Weave generated $239 million of fiscal 2025 revenue, up 17%, and $65.5 million in the first quarter of fiscal 2026, also up 17%, yet its market value sits well below the $1.4 billion peak. Francisco Partners raised more than $75 billion and previously bought AdvancedMD for $1.125 billion. (Link)
  2. Universal Health Services (NYSE: UHS) has closed its $835 million debt-financed acquisition of virtual behavioral care provider Talkspace (NASD: TALK). The transaction valued Talkspace at $5.25 per share and was financed with debt. Talkspace keeps its brand and organizational structure, with CEO Jon Cohen reporting directly to UHS President and CEO Marc Miller. The target reported $229 million in revenue, $4.8 million in net income and $15.8 million in adjusted EBITDA in 2025, and runs a virtual network of more than 6,000 behavioral health professionals. Behavioral health already generated about 43% of the buyer’s $17.4 billion 2025 revenue, and UHS expects the deal to be slightly accretive to adjusted net income in the first year after closing. (Link)
  3. Thoma Bravo has to take Accelerant (NYSE: ARX) private at $20.25 per share in an all-cash deal valuing the specialty insurance risk exchange above $4 billion, with existing backer Altamont Capital Partners rolling over. The offer is a 49% premium to Accelerant’s closing price on 12 August 2026. Altamont Capital Partners, which controls around 82% of voting rights, supports the deal, and Altamont and the founders intend to keep an equity interest alongside Thoma Bravo. Thoma Bravo has committed equity, so completion does not depend on additional financing, and shareholders receive a 6% annual ticking fee if insurance regulatory approvals delay closing. Senior partner A.J. Rohde tied the thesis to MGA market growth. (Link)
  4. BioMarin (NASD: BMRN) to acquire Alesta Therapeutics for $275 million BioMarin Pharmaceutical has agreed to acquire Alesta Therapeutics to gain ALE1, a clinical-stage oral small molecule for hypophosphatasia. BioMarin will pay $275 million upfront and up to $215 million in development and regulatory milestones. Alesta will spin out all non-ALE1 assets prior to closing. ALE1 is being evaluated in a Phase 1/2a trial and has the potential to become the first oral therapy for the rare genetic bone disease. Closing is expected this quarter. (Link)
  5. Cityblock Health has signed an all-stock agreement to acquire Homeward Health and separately raised a $116 million Series E led by General Catalyst. Financial details of the all-stock acquisition were not disclosed. The $116 million Series E was led by General Catalyst and takes total capital raised past $900 million, against a $400 million 2021 round that set a roughly $5.7 billion valuation. The company says it is not focused on an exit at this time. Cityblock serves almost 200,000 members at $2.2 billion of annualized revenue, up 77% year over year, and the two businesses together will serve nearly 250,000 people. (Link)
  6. R1 to acquire Humata Health, the AI prior authorization company, to extend its Phare Operating System into payer-provider authorization workflows. Pricing was not disclosed and both parties are private. The investment case is denial prevention: prior authorization is a top-three driver of denials, and a KFF survey found one-third of insured adults call it the biggest burden in accessing care. Humata’s agentic workflows match payer policy, build AI-driven clinical bundles and manage requests to final approval, delivering up to a 96% first-pass approval rate while cutting write-offs by 30%, rescheduled appointments by 83% and staff touches by 45%. R1 folds the capability into Phare Intelligence and Payer Atlas and uses it to sell adjacent modules. (Link)
  7. Goldman Sachs Asset Management-backed Advanced Recovery Systems has acquired Promises Behavioral Health from Assured Healthcare Partners. Terms were not disclosed. Promises was previously backed by Assured Healthcare Partners, which converted its debt into equity in late 2021, after BlueMountain Capital Management bought the assets of bankrupt Elements Behavioral Health in 2018. Combined, the company operates 24 facilities in 14 states across medical detox, inpatient, residential and outpatient services. Goldman halted an auction of Advanced Recovery Systems in January, and addiction treatment dealmaking has fallen sharply, with six closings in the first half of 2026 against 19 a year earlier.(Link)
  8. General Catalyst-backed Radial has acquired TMS Health Partners, the MSO behind Mindful Health Solutions, delivering an exit for previous backer Aisling Capital. Terms were not disclosed. Radial is less than a year into its holding period with General Catalyst and has multiplied its clinical footprint with a single transaction. The combination brings Radial to 27 clinics across seven states, most of them from Mindful Health Solutions. The deal also caps a quick turnaround for Aisling Capital. Radial supports clinics with drug and device procurement, billing and RadialOS, an AI clinical decision support tools. (Link)
  9. Flexpoint sells ArtesRx to Linden Capital Partners Flexpoint Ford has completed the sale of ArtesRx, its specialty behavioral health pharmacy platform, to Linden Capital Partners. Formed in 2023, ArtesRx focuses on complex medication regimens for patients with serious mental illness, substance use disorders, and intellectual and developmental disabilities. Under Flexpoint ownership the platform expanded from three pharmacies in a single state to 16 locations across 15 states through organic growth and targeted M&A. Financial terms were not disclosed. (Link)
  10. BPOC partners with Master Medical Equipment and ReNew Biomedical BPOC has made strategic investments in Master Medical Equipment and ReNew Biomedical, sister companies that provide capital equipment distribution, rental, repair and preventative maintenance services to the pre-hospital and post-acute markets. The Jackson, Tennessee-based businesses offer new and refurbished equipment along with biomedical service across a national footprint. Founder and CEO Mark Taylor will continue to lead the companies. Financial terms were not disclosed. (Link)
  11. Truehelm and QHP Capital-backed InformedDNA has divested its Genetic Testing Utilization Management business unit to Zyter, a subsidiary of global technology company Infinite. Terms were not disclosed. InformedDNA is a portfolio company of Truehelm and QHP Capital, and the sale follows the May 2026 divestiture of its Payment Integrity business unit. The sponsors are concentrating remaining capital behind DNAimpact, InformedDNA’s precision health platform, rather than running three businesses at once. The divested unit pairs genetics-trained specialists with evidence-based review for health plans, a capability that grows more valuable as genetic test volume and complexity compound. Truehelm partner and board member Conor Green described the process as sharpening InformedDNA’s focus. (Link)
  12. U.S. Oral Surgery Management, backed by Oak Hill Capital, has partnered with Cottonwood Oral & Maxillofacial Surgery of Albuquerque in its third New Mexico transaction. Terms were not disclosed and both parties are private. USOSM is a management services organization that works exclusively with oral and maxillofacial surgeons and now spans 31 states. The specialist-only mandate is the differentiator against general dental consolidators, and single-practice tuck-ins remain the primary growth mechanism. CEO Doug Drew pointed to clinical reputation, patient care and safety as the selection criteria for the practice. USOSM provides operational, financial and administrative support to surgeons alongside wealth creation. (Link)
  13. Integrated Dermatology has entered the Kentucky market through a partnership with Knuckles Dermatology, which now operates as Integrated Dermatology of Kentucky. Terms were not disclosed and both parties are private. The partnership took effect August 18, 2026 and covers patients in Corbin, Richmond and surrounding southeastern Kentucky communities. Dr. Knuckles continues to practice, and two board-certified family nurse practitioners, Lauren Hayes and Jordan Patterson, join to expand provider capacity. Established in 2004, Integrated Dermatology operates in nearly 30 states and offers dermatologists profit-sharing and full clinical autonomy while handling operational and administrative work centrally.(Link)
  14. Concentra (NYSE: CON) has completed the acquisition of four Minnesota Occupational Health medical centers in the Twin Cities, taking its statewide network to 10 sites. Terms were not disclosed. The four acquired centers sit in Coon Rapids, Eagan, St. Paul Midway and Shakopee, and began operating as Concentra on August 17. Concentra has served Minnesota since 2018 and will now run 10 medical centers across the state. The buyer also plans significant investment in the St. Paul Midway center to make it a regional flagship. The economics rest on density and employer cross-selling across injury care, physical therapy, drug testing and DOT exams. (Link)
  15. Momentum Health Partners has expanded its investment in Desert Pain Specialists, the Rancho Mirage, California interventional pain management practice it first backed in 2023. The amount was not disclosed. The Phoenix-based platform deployed additional capital into Desert Pain Specialists following the acquisition and integration of Dr. Roland Reinhart’s pain management practice. The new capital funds physician recruitment, service line expansion and operational growth across California’s Coachella Valley, where the practice has posted growth in new patient volumes since integrating. Partner Ryan Harper framed the follow-on as confidence in the team. Momentum invests across autism therapy, developmental therapies, behavioral health and specialty ambulatory care. (Link)
  16. SEVA has made a growth equity investment in healthcare price transparency company Serif Health, the first outside institutional capital the San Francisco business since 2020 launch. Terms were not disclosed. The round is Serif Health’s first outside institutional capital since it launched in 2020, and SEVA founder and managing partner Shalin Mehta joins the board. Serif cleans, validates and standardises pricing data from hundreds of payers and thousands of hospitals through its Signal platform, used by more than 250 organisations to benchmark rates, evaluate networks and track market dynamics. Proceeds accelerate sales and expand a pipeline of product features and data APIs, following the 2026 launch of Signal Ask, a plain-language query tool. (Link)
  17. Providence Equity Partners to acquire a majority stake in CheckedUp, with Varsity Healthcare Partners joining as strategic minority. Terms were not disclosed. Providence is acquiring alongside the co-founders, who continue to lead the company, and Varsity Healthcare Partners as a healthcare services-focused minority investor. CheckedUp reaches >17,000 specialty healthcare providers and 15 million patients through waiting-room televisions and interactive exam-room wallboards, and works with most of the top 40 pharmaceutical manufacturers. Providence is underwriting this as a digital out-of-home media asset, consistent with prior positions in OUTFRONT Media, DoubleVerify and Smartly.io. (Link)
  18. Cypress Ridge Capital-backed Cresso Health has partnered with Slate Financial, the Southwest Medicare and health insurance distributor. Terms were not disclosed. Cresso Health is backed by New York-based healthcare investor Cypress Ridge Capital. The logic is distribution roll-up economics. Slate gains access to Cresso’s carrier relationships, distribution infrastructure, proprietary marketing and lead-generation tools and compliance toolkit, while Cresso extends its field presence. CEO Frank Pistone described the goal as an omni-channel, multi-product platform serving the senior market. Cypress Ridge invests exclusively in healthcare with a thematic, growth-oriented approach. (Link)
  19. Rockmont Partners has exited RepScrubs, the automated scrubs dispensing platform, with THL named as acquirer in Healthcare DealHub’s headline. Terms were not disclosed. Healthcare DealHub titles the transaction as THL acquiring RepScrubs from Rockmont Partners, while the deal note itself describes the buyer as undisclosed. Rockmont led a secondary purchase in the business in 2024, making this a short hold. RepScrubs runs an automated scrubs dispensing platform that manages vendor credentialing and enforces policy compliance for perioperative vendors at hospitals and surgery centers. The asset sits in digital and health technology, which has recorded 289 tracked deals year to date. (Link)
  20. Berks Community Health Center to merge with Lancaster-based Union Community Care, a distress-driven nonprofit combination pending regulatory approval. No purchase price applies. Board vice chair Missy Orlando named two financial triggers, starting with a sharp drop in federal Medicaid funding from January that could cost roughly 100,000 Berks County residents their benefits. The center has also struggled to collect patient payments and lost several providers over the past year. Union Community Care operates 25 locations across Lancaster, Lebanon and Chester counties, covering family medicine, urgent care, dental, school-based care, behavioral health and pharmacy. (Link)
  21. Mitsui Chemicals (Tokyo: 4183) has completed its acquisition of Utah-based dental products maker Ultradent Products, making it a wholly owned subsidiary alongside existing dental unit Kulzer. The deal closed on August 14, ahead of the September 2026 schedule, after competition and investment approvals came through early. Mitsui is making oral care the third earnings pillar of its Life & Healthcare Solutions segment and targeting the number two position in global dental materials. The company expects more than $40 million in annual synergy by fiscal 2030. Integration moves the oral care global headquarters to the United States, with Ultradent CEO Dirk Jeffs also taking over as Kulzer CEO while Kulzer’s Chris Holden becomes Chief Strategy and Integration Officer of MC Dental Holdings America.(Link)
  22. Osage Venture Partners-backed Curavit Clinical Research has acquired the CRO assets of Lindus Health, which is shifting to its own therapeutic pipeline as Lindus Therapeutics. Terms were not disclosed. The transaction follows Lindus shifting focus to developing its own pipeline of therapeutic assets. What Curavit bought is European delivery capability, not scale for its own sake: the combined business can now run decentralized, hybrid and traditional trials across North America and Europe under one operational partner. Nate Lentz, managing partner at Osage Venture Partners and a Curavit board member, tied the thesis to sponsors needing more flexible, technology-enabled approaches to generating clinical evidence. CEO Joel Morse positioned the platform against both regional niche CROs and legacy providers. (Link)

Venture Deals and Other

  1. 8VC and Town Hall Ventures have led a $53 million Series D in Hopscotch Primary Care. 8VC and Town Hall Ventures led the round, with existing investors aMoon Fund, Citi Impact Fund, Alumni Ventures and K2 HealthVentures participating and new investors including the Autism Impact Fund, Kleiner Perkins chairman John Doerr, Heritage Provider Network founder Dr. Richard Merkin and the Leon Levine Foundation. Founded in 2021, Hopscotch serves more than 15,000 patients across the rural Southeast, concentrated in western North Carolina. Investors have hard numbers to point at: a Net Promoter Score of 89, patient retention above 90%, medical loss ratio improvement of more than 25 percentage points over two years and profitable operations in western North Carolina. (Link)
  2. Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund and JSL Health Capital have funded Network Bio’s $50 million launch alongside an NVIDIA partnership. Network Bio, a Palo Alto company building AI models trained on human biological data, launched on August 19 with $50 million from investors including Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund and JSL Health Capital. The money funds a research network with Mass General Brigham, the University of Pennsylvania and the University of Colorado Anschutz, supplying tissue and blood samples paired with longitudinal clinical outcomes across immunology, metabolic, cardiovascular and autoimmune disease. Investors are paying for exclusive data access rather than a clinical asset. The launch came with an NVIDIA partnership to scale the models. (Link)
  3. InnovaHealth Partners led Channel Medsystems’ Series C to $30 million, backing the commercial expansion of the Cerene endometrial cryotherapy platform. The Berkeley medical technology company has reached $30 million in an ongoing Series C led by InnovaHealth Partners. InnovaHealth has backed Channel Medsystems since 2021. Proceeds fund commercial organization expansion, physician and patient awareness, professional education and training, clinical evidence generation and market development infrastructure. The raise follows a commercial relaunch of the platform. Founder and Managing Partner Mortimer Berkowitz III pointed to unmet need in women’s health backed by clinical evidence and an experienced leadership team. (Link)
  4. MaxQ Medical raises $31.5 million Series A backed by Olympus MaxQ Medical has closed a $31.5 million Series A led by Atlantic Blue Ventures, S3 Ventures and Olympus Innovation Ventures, with participation from Hillside Capital. The financing advances the company’s transurethral imaging-and-therapy platform for prostate disease, the first spinout from Orchard Ultrasound Innovation. The system combines real-time imaging with tissue-selective therapy in a single outpatient procedure, initially targeting BPH with planned expansion into focal therapy for prostate cancer. Proceeds support clinical program advancement and team expansion. (Link)
  5. Leal Therapeutics announces $30 million Series A extension Leal Therapeutics has completed a $30 million second close of its Series A, adding Eli Lilly as a new investor alongside existing backers OrbiMed, Newpath Partners, Euclidean Capital, SV Health Investors’ Dementia Discovery Fund and others. Proceeds will advance LTX-001, a first-in-class brain-penetrant oral GLS1 inhibitor, through initial readout of its newly initiated Phase 1b/2a trial in schizophrenia, and progress LTX-002 through additional dosing cohorts in an ongoing Phase 1/2 ALS study. (Link)
  6. Werewolf Therapeutics and Ambros Therapeutics announce merger and concurrent $150 million private placement Werewolf Therapeutics (Nasdaq: HOWL) and Ambros Therapeutics have entered an all-stock merger agreement accompanied by an oversubscribed $150 million private placement co-led by RA Capital and Janus Henderson. The combined company, to operate as Ambros Therapeutics and trade as AMBX, will advance neridronate in the pivotal CRPS-RISE Phase 3 trial for Complex Regional Pain Syndrome Type 1. Capital is expected to fund operations through Phase 3 topline results, planned NDA submission and into the first half of 2029. (Link)
  7. Gossamer Bio announces up to $250 million structured private placement Gossamer Bio has arranged a structured private placement of up to $250 million, including $150 million of committed capital, to fund development of seralutinib through potential FDA approval. The financing extends runway for late-stage clinical and regulatory activities surrounding the company’s lead pulmonary arterial hypertension program. (Link)
  8. Biotechnology investor Bob Nelsen has led a $20 million round in Astromech, joined by Peak 6, NeoGenesis Capital, Builders VC and CAZ Investments, lifting the Colossal Biosciences spinout to a $3.8 billion valuation. The round was led by Bob Nelsen with participation from Peak 6, NeoGenesis Capital, Builders VC and CAZ Investments, bringing total capital raised to $60 million. The valuation is unusual relative to check size, and what investors are buying is founder pedigree and a data position rather than near-term revenue. Astromech was co-founded by Ben Lamm and geneticist George Church, spun out of Colossal Biosciences, and uses 3.8 billion years of evolutionary history as a primary training signal. Longevity is the proving ground, with 46 longevity-associated genes mapped so far. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 17th, 2026

LECO_Weekly-Healthcare-News_8-17-2026Download

Healthcare Weekly News and Deals

  1. Teledyne Technologies (NYSE: TDY) has entered a definitive agreement to acquire Varex Imaging Corporation (NASD: VREX) for $18.90 per share in cash, valuing the X-ray component maker at approximately $1.1 billion. Teledyne is paying roughly $1.1 billion in cash for Varex, extending a medical imaging build-out that began with the 2011 Teledyne DALSA purchase and the 2017 Teledyne e2v deal. Executive Chairman Robert Mehrabian framed the fit as complementary with minimal overlap: Teledyne lacks detectors for high-radiation oncology environments and photon-counting technology, both of which Varex supplies. Both boards approved unanimously; closing is targeted for early 2027 pending regulatory and Varex shareholder approval. Shareholder litigation is reportedly being weighed over whether the price adequately compensates Varex holders. (Link)
  2. Astorg has completed the carve-out acquisition of Thermo Fisher Scientific’s (NYSE: TMO) global microbiology business Astorg has closed a $1.075 billion carve-out of Thermo Fisher’s microbiology unit, structured as cash plus a $50 million seller note. The asset generated $645 million of 2025 revenue inside Thermo Fisher’s Specialty Diagnostics segment, serving over 15,000 customers across more than 100 countries with roughly 2,400 employees at 13 manufacturing and R&D sites. Judith Charpentier, Co-Managing Partner and Head of Healthcare at Astorg, positioned it as the complex-carve-out profile the firm targets. The business will run independently under CEO Dirk Bontridder and rebrand later in 2026. (Link)
  3. Affordable Care, LLC has completed a recapitalization transferring ownership to its existing lenders, cutting debt by approximately $1.0 billion and injecting $75 million of new capital. Affordable Care, the Morrisville, North Carolina dental support organisation, has closed a balance-sheet restructuring that hands ownership to its lender group. The transaction reduces debt by roughly 65%, or about $1.0 billion, provides $75 million of fresh capital and extends maturities to 2031. This is a creditor-led ownership change rather than a sponsor sale: the incoming lender owners are positioned as aligned with a longer-horizon plan. Deleveraging is intended to free capacity for reinvestment in supported practices, clinical capability, operating infrastructure and patient experience — a familiar reset for over-levered DSO platforms. (Link)
  4. PTC Therapeutics (NASD:PTCT) to acquire ST-920 Fabry disease gene therapy program for $111 million upfront plus milestones PTC Therapeutics has been selected as the winning bidder to acquire ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics in a competitive bankruptcy auction. Terms include $111 million upfront and up to $100 million in contingent regulatory milestones. A rolling BLA submission is expected to be completed in Q4 2026, with potential commercial launch in 2027. The deal leverages PTC’s existing rare disease commercial infrastructure. (Link)
  5. Fulcrum Therapeutics (NASD:FULC) and Slate Medicines announce merger agreement with concurrent $245 million private placement Fulcrum Therapeutics and privately held Slate Medicines have entered a definitive all-stock merger agreement. The combined company will operate as Slate Medicines and focus on next-generation migraine therapies, led by clinical-stage candidate SLTE-1009. Concurrently, Slate secured an oversubscribed $245 million private placement from a syndicate including Frazier Life Sciences, Forbion, RA Capital and others, expected to fund operations into 2029. Closing is targeted for the fourth quarter of 2026. (Link)
  6. EnableComp has acquired Helix Advisory, a Cincinnati, Ohio-based revenue recovery firm, to advance Zero Balance Review technology within its complex revenue recovery platform. EnableComp, the Franklin, Tennessee complex revenue cycle management provider, has acquired Ohio-based Helix Advisory. Terms were undisclosed and both parties are private. The acquisition closes a product gap: EnableComp already recovers roughly $3 billion annually across more than 1,000 hospitals in complex claims and denials, but lacked zero balance review — claims already paid, closed and filed, but paid incorrectly. Helix contributes underpayment detection beyond rules-based logic, clinical signal detection and root-cause analytics, folded into the e360 RCM platform. Founder Zack Higbie joins as VP of Revenue Recovery Products, citing early client net revenue improvements exceeding 2%. (Link)
  7. CHG Healthcare has acquired KREWE Anesthesia, a CRNA-founded staffing firm, to expand certified registered nurse anesthetist staffing and managed anesthesia services. CHG Healthcare, the Salt Lake City-area physician and advanced-practice workforce company, has acquired KREWE Anesthesia. Terms were undisclosed and both parties are private. The investment case rests on scarcity: CHG’s own research ranks CRNAs among the hardest advanced-practice roles to fill nationally, with rural hospitals especially dependent on CRNA-led anesthesia to sustain surgical volume. Founded in 2022, KREWE reports roughly 84% annual clinician retention, materially above locum tenens benchmarks. CEO Leslie Snavely framed the deal as capability plus cultural fit. Founders Gavin Baker and Chase Chiasson remain as CEO and President. (Link)
  8. Viome Life Sciences has acquired Circulate Health, the therapeutic plasma exchange provider, adding clinical delivery to its molecular diagnostics and precision nutrition platform. Viome Life Sciences, the Bellevue, Washington preventive health company founded in 2016, has acquired Circulate Health. Financial terms were not disclosed and both are private. The acquisition converts Viome from a diagnostics-and-recommendations business into one owning the intervention layer, expanding the combined platform to more than 200 partner clinics. Circulate contributes physician-guided therapeutic plasma exchange delivered outside hospital settings, with published research associating its protocol with an average 2.6-year biological age reduction and measurable microplastic reduction. Founder Naveen Jain framed the thesis around measurable, repeatable health improvement. Circulate CEO Brad Younggren becomes president of Viome PRO. (Link)
  9. Kyndryl (NYSE: KD) has agreed to acquire Healthcare IT Leaders, LLC, an enterprise IT services provider to hospitals and health systems, to accelerate AI-led modernization for providers and payors. Kyndryl is buying Healthcare IT Leaders to bolt a consulting and application managed services layer onto its existing infrastructure position in U.S. healthcare. Terms were undisclosed. Jamie Rutledge, president of Kyndryl U.S., framed demand as coming from providers under pressure across clinical, operational and workforce systems while maintaining resiliency and compliance. Strategically, this moves Kyndryl up the stack: it already runs large regulated IT environments, and the target deepens relationships with national health systems across federal, academic, pediatric and regional segments. Closing is expected in Kyndryl’s fiscal 2027 second quarter. (Link)
  10. DermCare Management, LLC and U.S. Dermatology Partners have completed a strategic combination creating one of the largest dermatology group practices in the United States, spanning 12 states. DermCare Management and U.S. Dermatology Partners have closed a combination uniting two physician-led platforms across 12 states. Financial terms were not disclosed and both are privately held. The combined organisation will serve more than three million patients annually — DermCare contributes over 270 providers and more than one million patients across Florida, Texas, Virginia, North Carolina and California, while USDP treats over two million patients across nine states. Scale economics drive the rationale: national clinical trial infrastructure, expanded provider education and shared practice technology. DermCare founder Jeffrey Schillinger becomes Executive Chair; USDP’s Paul Singh leads as President and CEO. (Link)
  11. LLR Partners and LNK Partners-backed Schweiger Dermatology Group has acquired Saratoga Dermatology, expanding its footprint across the greater Albany, New York market. Schweiger Dermatology Group, backed by private equity sponsors LLR Partners and LNK Partners, acquired Saratoga Dermatology on August 5, 2026. Financial terms of the private transaction were not disclosed. The target operates outpatient clinics in Saratoga Springs and Clifton Park under Drs. Jean Buhac, Christopher Heath and John Buhac, delivering medical, surgical and cosmetic dermatology. The sponsors’ model is density plus centralisation: SDG already runs more than 65 offices and roughly 200 providers across the Northeast, and the addition concentrates upstate New York coverage while folding the practice into shared operational infrastructure. (Link)
  12. Little Rock, Arkansas-based Rock Dental Brands has partnered with TLC Pediatric Dentistry & Orthodontics, a Tampa, Florida specialty practice led by Dwight Sanjuan, DMD, and Robertzon Guloy, DMD. Rock Dental Brands has added TLC Pediatric Dentistry & Orthodontics in Tampa, extending its multi-specialty DSO platform into the Florida market. Deal terms were not disclosed and both parties are private. Launched in 2003, TLC pairs pediatric dentistry with orthodontics under two clinician owners, a dual-specialty configuration consolidators favour because it captures a patient across a longer treatment arc and internalises referral flow. Dr. Sanjuan holds memberships in the American Academy of Pediatric Dentistry, the Florida Academy of Pediatric Dentistry and the International Association of Pediatric Dentistry. The transaction reflects continued single-practice tuck-in activity in dental support organisations. (Link)
  13. DuneGlass Capital-backed Phase 1 Equity has acquired a multi-site orthodontic practice in North Dakota, marking its fourth practice addition of 2026 and its 23rd doctor. Phase 1 Equity, the Chicago-headquartered doctor-owned platform launched by DuneGlass Capital in 2022, has added a multi-site North Dakota orthodontic practice. Terms were undisclosed. The transaction is Phase 1’s fourth addition of 2026, its first in North Dakota, and lifts the platform to 23 doctors across 33 locations nationally. The differentiator is the sponsor’s proprietary Doctor Equity model, under which participating orthodontists and pediatric dentists retain full clinical and practice-level decision rights while accessing private-equity economics and network scale. DuneGlass Managing Partner Ryan Graham co-founded the platform as an alternative to conventional dental consolidation. (Link)
  14. WindRose Health Investors, LLC has completed the recapitalization of Verified Clinical Trials, LLC, the clinical trial subject registry provider, and appointed Howard Miller as Chief Executive Officer. WindRose Health Investors, the New York healthcare private equity firm managing roughly $8 billion, has recapitalized Verified Clinical Trials. Terms were undisclosed. Partner CJ Burnes described VCT’s platform as proactively reducing downstream risk across the clinical research chain. The underwriting logic is infrastructure rather than therapeutics: VCT’s secure global database detects duplicate enrolment and protocol violations at screening, and sixteen years of proprietary data assets create a defensible position. Capital funds data and analytics expansion for sponsors, CROs and trial sites. Founders Mitchell Efros, MD and Kerri Weingard, ANP remain actively involved post-close. (Link)
  15. Integrity, LLC has partnered with Meraz Health Insurance Agency, the Temecula, California Medicare-focused independent marketing organization led by Manuel “Manny” Meraz. Integrity, the Dallas-headquartered distributor of life and health insurance and provider of wealth and retirement solutions, has added Meraz Health Insurance Agency to its partner network. Financial details were not disclosed and both parties are private. The transaction follows Integrity’s established roll-up pattern in independent marketing organizations, where acquired agencies gain access to the IntegrityCONNECT AI platform, Ask Integrity voice assistant, marketing infrastructure and carrier breadth. Meraz brings a decade-long Medicare Advantage, prescription drug and Medicare supplement book with deep Latino community distribution — a demographic channel with structural growth in Medicare enrolment. (Link)
  16. Denver-based Mountaingate Capital has fully exited its investment in Relevate Health, the Cincinnati, Ohio-based healthcare commercialization platform, after a six-year partnership. Mountaingate Capital, a lower-middle-market firm partnering with founders and entrepreneurs, has exited Ohio-based Relevate Health, closing August 5, 2026. Terms were undisclosed and the buyer was not identified. Mountaingate first invested in 2020, and the value-creation plan ran through four add-on acquisitions plus investment in Relevate’s proprietary ELE Decision Engine, product suite, infrastructure and leadership team. Co-Founder and Managing Director Bruce Rogers framed the outcome as validation of the original thesis. The firm characterises it as another strong result in tech-enabled, analytics-driven marketing services — a sector where Mountaingate has now realised repeat exits. (Link)
  17. Global systems integrator Myriad360 has acquired the assets of healthcare-focused F3 Technology Partners, pushing the combined platform past the $1 billion annual revenue. Myriad360, the West Deptford, New Jersey-based systems integrator, has purchased the assets of F3 Technology Partners, a West Hartford, Connecticut provider with a longstanding healthcare and financial services vertical. Terms were not disclosed and both are private. The deal follows Myriad360’s February 2026 acquisition of Ohio-based AdvizeX Technologies, which alone created a roughly $900 million run-rate platform; F3 carries the combined business across $1 billion. The strategic driver is channel consolidation — vendor programmes increasingly favour scaled partners, and healthcare vertical depth commands premium positioning in a fragmented integrator market. (Link)
  18. Gridiron Capital, LLC has partnered with van den Boom & Associates, the San Diego-based outsourced back-office services provider to emerging life sciences companies, under founder Esther van den Boom’s continued leadership. Gridiron Capital, the New Canaan, Connecticut firm focused on founders, entrepreneurs and management teams, has invested in van den Boom & Associates. Financial terms were not disclosed. The deal advances Gridiron’s Outsourced Pharma Services Thematic Area of Expertise and builds on prior healthcare and pharma-adjacent services investments. Principal Aaron Stoppelmann framed the thesis around two converging trends: growth in venture-backed life sciences companies and their preference for specialised operational partners. vdB&A serves 160-plus active clients with 150-plus professionals across finance, HR, contract management, compliance and a newly launched IT managed services line. (Link)
  19. Marlin Equity Partners-backed Radar Healthcare has acquired patient experience and patient-reported outcomes platform Cemplicity, following its earlier purchase of EIDO Healthcare. Radar Healthcare, the quality, risk and compliance software provider backed by Marlin Equity Partners, has acquired Cemplicity. Terms were undisclosed and both parties are private. The sponsor thesis is adjacency stacking rather than scale: Cemplicity contributes patient experience measurement, patient-reported outcomes and real-time patient insight, which Radar pairs with its existing quality, risk and improvement workflows. Chief Executive Edward Bellamy positioned the logic as connecting what patients report to the workflows needed to act on it. The deal follows Radar’s acquisition of digital consent provider EIDO Healthcare, extending a buy-and-build across the quality-and-safety software stack. (Link)
  20. The Riverside Company adds Yellow Emperor to Western Botanicals The Riverside Company has made Yellow Emperor its first add-on investment for portfolio company Western Botanicals. The Eugene, Oregon-based CDMO specializes in custom liquid dietary supplement formulations, providing end-to-end services from ingredient sourcing through manufacturing, bottling and packaging. The combination deepens Western Botanicals’ liquid capabilities and strengthens its position as a formulator and manufacturing partner for health and wellness brands. (Link)
  21. Sarnova, Patricia Industries portfolio company, acquires Mercury Medical Sarnova, a national specialty distributor of emergency medical services and acute care products, has acquired Mercury Medical. The Clearwater, Florida-based company designs, manufactures and distributes critical care and emergency medical devices. The deal expands Sarnova’s product portfolio across its Bound Tree Medical, Cardio Partners, Emergency Medical Products and Tri-anim Health Services units. (Link)
  22. Livingbridge has put teleradiology group Everlight Radiology up for sale at around $1 billion, with Radiology Partners reported to be the front-runner UK mid-market firm Livingbridge is running a roughly $1 billion sale of Everlight Radiology. The process is now in its late stages, with Radiology Partners reported to be leading. An Everlight exit would hand Livingbridge a large realisation from a cross-border teleradiology asset, while a Radiology Partners win would extend the US-based radiology platform’s reach into Australian and UK night-hawking volumes. Radiology reading remains one of the most actively consolidated healthcare services niches for private capital. (Link)
  23. Curium acquires Abscint, expanding its PET radiodiagnostic pipeline in oncology Curium, a global radiopharmaceutical company, has completed the acquisition of Abscint SA, a Belgian clinical-stage company developing PET imaging agents for oncology. The deal adds ABS-011, an investigational gallium-68-labeled PET tracer targeting HER2 that is currently in a Phase 2b trial. Curium gains global rights to develop, manufacture and commercialize the asset, strengthening its radiodiagnostic capabilities in breast and gastric cancers. (Link)

Venture Deals and Other

  1. Soleus Capital has led a $110 million Series C and debt financing in Bridge to Life Ltd., with Lauxera Capital Partners participating and Soleus Capital Credit Opportunities Fund providing the debt tranche. Soleus Capital, the Greenwich firm with roughly $3.5 billion in assets under management, led the equity alongside Lauxera Capital Partners, which manages over $1 billion across 14 healthtech portfolio companies; Bridge to Life directors, officers and employees also participated. Partner Ben Lund cited the pairing of an established preservation franchise with a newly FDA-cleared perfusion platform. Proceeds refinance the Perceptive Credit Funds facility — cutting leverage and interest cost — and fund the VitaSmart HOPE System commercial build-out to every U.S. transplant center, plus a viability assessment tool and multi-organ pipeline. (Link)
  2. Bessemer Venture Partners has led a $50 million Series B in Flagler Health, with participation from SignalFire, Alumni Ventures, Streamlined, 186 Ventures, Proof VC, Tribeca Venture Partners and Offscript. Bessemer Venture Partners led the $50 million Series B for New York-based Flagler Health, taking total funding to $63 million. Partner Steve Kraus pointed to the founding team’s combination of healthcare operations experience, clinical authority and AI expertise applied to a large underserved market. Investors are backing demonstrated unit economics rather than promise: in under three years Flagler has scaled to thousands of providers across more than 36 states, delivering an average $164,000 in additional annual revenue per provider, with 87% of patients reporting improvement. Musculoskeletal care represents over $400 B in annual U.S. spend. (Link)
  3. OG Venture Partners and M Ventures, the corporate venture arm of Merck KGaA, Darmstadt, Germany (ETR: MRK), have co-led a $36 million Series A in Remepy, joined by NFX, Qumra Capital, Tadmor Group, TechAviv and Vine Ventures. OG Venture Partners and M Ventures, the strategic venture arm of Merck KGaA (ETR: MRK), led Remepy’s $36 million Series A, lifting total capital raised to $62 million. The strategic investor’s participation is notable given Merck KGaA’s existing hybrid drug development partnership with Remepy covering multiple indications, starting with rare tumours. Proceeds fund a global Phase III trial of lead asset Hybridopa in Parkinson’s disease, commencing in the fourth quarter of 2026, following positive Phase IIa motor and non-motor data. Investors are betting on evolving U.S. regulatory frameworks for drug-software combination products. (Link)
  4. Redmile Group, Vsquared Ventures and Kindred Capital have co-led a $25 million seed round in Bios Life, which signed a multi-year data alliance with Tempus AI (NASD: TEM). Redmile, Vsquared Ventures and Kindred Capital led the $25 million seed for Bios Life, joined by healthcare and technology investors across the United States and Europe — an unusually deep syndicate for a company emerging from stealth. Investors are underwriting a founder-pedigree and data-moat thesis: CEO Ryan Richardson was BioNTech’s chief strategy officer and chaired InstaDeep, and the company holds commercial rights to the Nucleotide Transformer genomics foundation model. The Tempus alliance supplies de-identified multi-modal oncology data for training, with Tempus-owned Ambry Genetics adding hereditary testing. Launch is slated for second-half 2026. (Link)
  5. Battery Ventures has made a significant growth investment in Vetspire, the AI operating system for veterinary practices, carving it out as a standalone company from Thrive Pet Healthcare. Battery Ventures, a global technology-focused investment firm founded in 1983, is backing Vetspire as an independent business, with Thrive Pet Healthcare retaining no ownership going forward while remaining a long-term customer. Terms were undisclosed. General Partner Chelsea Stoner cited timing: Covid-era adopted pets are aging into higher care needs. Battery brings a track record in specialty-healthcare EHR and practice-management platforms including Brightree, ClearCare, ContinuumCloud, Curve Dental and WebPT. Vetspire runs at more than 800 hospitals and clinics; Zachary Seely joins as CEO. (Link)
  6. XiFin, Inc. has made a strategic investment in Denver-based Notable Systems as part of Notable’s Series B financing, alongside a multi-year agentic AI alliance across revenue cycle management. XiFin has invested in Notable Systems’ Series B while committing to a multi-year technology alliance. The investment amount was not disclosed and both companies are private. Executive Chair and CEO Lâle White framed the capital commitment as reinforcing XiFin’s position in intelligent revenue cycle management. Notable’s document intelligence will be embedded into the XiFin Empower AI RCM ecosystem, targeting requisitions, prescriptions, medical records and payer correspondence. Notable serves enterprise DME providers including Orthofix (NASD: OFIX) and National Seating & Mobility. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 10th, 2026

LECO_Weekly-Healthcare-News_8-10-2026Download

Healthcare Weekly News and Deals

  1. Hinge Health, Inc. (NYSE: HNGE) has signed a definitive agreement to acquire virtual-first digestive care provider Cylinder Health, Inc. for $105 million in cash. Hinge Health (NYSE: HNGE) is deploying $105 million of cash to enter gastrointestinal care, a category it sizes at $135 billion of annual U.S. medical spend affecting roughly one in four adults. Cylinder brings nearly 100 clients across two million lives, relationships with two of the three largest PBMs and three of the top five health plans by self-insured share, and more than 150,000 patients treated with a clinically validated ROI. The rationale is cross-sell economics: Hinge cites high comorbidity with its existing MSK and migraine populations. An integrated GI program launches in 2027; closing is expected in the third quarter of 2026. (Link)
  2. KKR has agreed to acquire Integer Holdings Corporation (NYSE: ITGR), the Plano, Texas-based medical device contract development and manufacturing organization, in an all-cash take-private valuing the company at an enterprise value of approximately $5.7 billion. KKR is paying $127.00 per share in cash for Integer Holdings (NYSE: ITGR), a 51.8% premium to Integer’s April 29, 2026 close and 28.8% over its 30-day VWAP as of July 31, 2026. The deal follows a board-led strategic review launched in April and is financed with equity from KKR-managed funds plus committed debt, with no financing contingency. KKR, which reported $796 billion of assets under management at quarter end, deepens a healthcare book that already includes the 2018 Envision take-private, and plans to establish an employee ownership program at Integer. Closing is expected by year-end 2026 and Integer will delist from the NYSE. (Link)
  3. Teleflex Incorporated (NYSE: TFX) has completed the divestiture of its OEM business to private equity firms Montagu and Kohlberg for $1.5 billion in cash, with the unit relaunched as Ingenyx. Montagu and Kohlberg have closed their $1.5 billion all-cash purchase of Teleflex’s (NYSE: TFX) contract manufacturing arm, carved out via Lotus US Bidco Inc. and rebranded Ingenyx. Teleflex estimates approximately $1.25 billion in after-tax proceeds and will apply them to $800 million of debt reduction and completion of a $1 billion share repurchase authorization. The sale was first announced in December 2025 alongside the Acute Care unit at $2.03 billion of combined value. For Teleflex, the exit concentrates the portfolio on Vascular Access, Interventional and Surgical; for the sponsors, it delivers a standalone medtech CDMO platform. (Link)
  4. Nordic Capital has agreed to carve out BWX Technologies, Inc.’s (NYSE: BWXT) medical business, including BWXT Medical and Kinectrics’ stable medical isotopes unit, in a transaction valued at up to $800 million. Nordic Capital, which manages roughly EUR 39 billion and runs a dedicated healthcare franchise, is acquiring BWXT’s (NYSE: BWXT) radiopharmaceutical platform in a carve-out valued at up to $800 million. BWXT has roughly tripled the unit’s revenue since buying it in 2018 and will retain a meaningful minority stake, allowing it to redeploy capital toward nuclear national security and commercial nuclear power. Partner Christian Hedegaard framed radiopharmaceuticals as sitting at the intersection of Nordic’s pharmaceutical and life sciences track record. The transaction is subject to customary regulatory approvals and is expected to close by the end of 2026. (Link)
  5. iRhythm Technologies, Inc. (NASD: IRTC) has agreed to acquire San Jose-based wearable biosensor company VitalConnect for $287.5 million, comprising $237.5 million in cash and approximately $50 million in iRhythm stock. iRhythm (NASDAQ: IRTC) is paying $287.5 million for VitalConnect, a private FDA-cleared biosensor platform running at an approximately $65 million annual revenue run rate, in a move that pushes iRhythm deeper into mobile cardiac telemetry. The deal was disclosed alongside 2Q26 results showing 20.1% year-over-year revenue growth and a $50 million patent settlement with Baxter. BTIG’s Marie Thibault called the deal surprising and expects mixed investor reaction, flagging concerns it could mask an MCT slowdown while noting the timing likely reflects VitalConnect’s capital needs. Management expects revenue contribution from 2027; closing is targeted by year-end. (Link)
  6. Jazz Pharmaceuticals (NASD:JAZZ) to acquire Actio Biosciences for $820 million upfront plus up to $500 million in milestones Jazz Pharmaceuticals (NASDAQ: JAZZ) has agreed to acquire privately held Actio Biosciences for $820 million in cash upfront and up to $500 million in contingent payments. The deal adds ABS-1230, a clinical-stage precision therapy targeting KCNT1+ epilepsy, a rare and severe developmental epileptic encephalopathy with no FDA-approved treatments. Jazz will also take a minority stake in a new spin-out company focused on other genetic rare neurological diseases. Closing is expected in the fourth quarter of 2026. (Link)
  7. Tarsus Pharmaceuticals (NASD:TARS) to acquire Alkeus Pharmaceuticals for approximately $450 million upfront plus up to $350 million in milestones Tarsus Pharmaceuticals (NASDAQ: TARS) has entered a definitive agreement to acquire Alkeus Pharmaceuticals, adding gildeuretinol (ALK-001), a Phase 3 oral investigational therapy for Stargardt disease. Consideration consists of roughly $270 million in cash and $180 million in Tarsus stock, plus up to $350 million in regulatory and commercial milestones and low single-digit royalties. The asset has Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations; Phase 3 NORTHSTAR topline data are expected in the second half of 2029. Closing is anticipated in 2026. (Link)
  8. Supernus Pharmaceuticals (NASD:SUPN) and Indivior Pharmaceuticals (NASD:INDV) to merge in all-stock transaction, creating a diversified CNS company Supernus Pharmaceuticals (NASDAQ: SUPN) and Indivior Pharmaceuticals (NASDAQ: INDV) have agreed to combine in a tax-free all-stock merger of equals. The combined company, to be named Supernus, Inc., is expected to generate approximately $2.2 billion in pro forma annual revenue and $125 million in annual cost synergies. Indivior stockholders will receive a $1 billion special cash dividend immediately prior to closing and will own about 56.5% of the combined entity. Jack Khattar will serve as CEO. Closing is targeted for the fourth quarter of 2026. (Link)
  9. Keensight Capital-backed Isto Biologics has acquired NovaBone Products LLC from Halma plc (LSE: HLMA) for approximately $60 million, expanding its bone graft substitutes platform. Keensight Capital, a pan-European growth buyout manager, has supported portfolio company Isto Biologics in acquiring NovaBone from Halma (LSE: HLMA) for a total consideration of roughly $60 million on a cash-free, debt-free basis. Completed just ten months after Keensight’s investment, this is Isto’s first bolt-on and the opening move in an explicit buy-and-build toward a transatlantic orthobiologics leader. Partners Amit Karna and David Piccoli cited product breadth and geographic reach as the value drivers. Alachua, Florida-based NovaBone sells bioactive glass synthetic grafts in over 40 countries across spine, orthopedic, trauma, extremities and dental applications. (Link)
  10. Eir Partners Capital has made a strategic investment in ClaimsBridge, which simultaneously acquired dialysis cost-containment specialist DialysisPPO, expanding its healthcare cost management ecosystem. Eir Partners Capital, a private equity firm focused on healthcare technology and tech-enabled services, has backed Arnold, Maryland-based ClaimsBridge in a dual transaction announced August 6, 2026. Terms were undisclosed. Founder and CEO Brett Carlson framed the thesis around ClaimsBridge sitting at the point in the claims workflow where pricing and routing decisions are made. The capital funds product development, platform expansion and further M&A. Alongside the investment, ClaimsBridge acquired DialysisPPO, founded 2006, whose patented program has saved payers over $325 million by capturing Medicare savings on dialysis claims without the usual thirty-month coordination period. (Link)
  11. The Difference Card, a Stone Point Capital portfolio company, has acquired healthcare analytics business HealthCorum, expanding its data, provider-scoring and AI navigation capabilities. The Difference Card, the employer health benefits cost-containment platform acquired by Stone Point Capital from Northlane Capital Partners in 2025, has bought HealthCorum. Financial terms were undisclosed. The acquisition adds provider quality scoring across more than 1.5 million providers and over 90 medical subspecialties, folding into the company’s Provider Lookup Manager Tool, plus an AI Navigator supporting natural-language provider search. The strategic logic is margin-relevant: pairing plan-design savings with steerage toward higher-quality, lower-cost providers deepens the value proposition to self-funded employers facing rising trend, and moves the platform from pure cost containment toward navigation. (Link)
  12. Beacon Behavioral Partners, based in Louisiana, has partnered with AR Psychiatric and Counseling Center, marking the physician-led behavioral health expansion into Georgia. Beacon Behavioral Partners, a Baton Rouge-headquartered network of independent interventional psychiatric practices, has entered Georgia through a partnership with AR Psychiatric and Counseling Center. Financial terms were undisclosed and both organisations are private. ARPCC operates two locations serving Valdosta, Tifton and South Georgia under co-lead psychiatrists Anil Gupta, MD, and Bhavesh Patel, MD, who retain the physician-led model. SVP of Business Development Todd Mudd positioned the transaction as preserving clinical autonomy while funding growth. Beacon’s model removes operational burden in exchange for scale, and the platform reported more than 250 providers across 45 locations as of its last disclosed count. (Link)
  13. Bookmark Medical, a provider-led platform has acquired Village Medical Michigan, including Huron Valley Practice Affiliates,  expanding to Michigan and four other states. Bookmark Medical, the Nashville-based primary care platform rebranded from Village Medical earlier in 2026, closed its Michigan entry effective August 3, 2026. Financial terms were undisclosed and both parties are private. The transaction adds seven primary care practices, a diagnostic center and Huron Valley Practice Affiliates, an independent physician organization, comprising roughly 40 providers, over 350 employees and more than 40,000 patients across Southeast Michigan. CEO Benson Sloan and Chief Physician Executive David Hatfield framed the deal around density and provider support. Bookmark now operates across Arizona, Massachusetts, Michigan and Tennessee, with the physician organization adding affiliated-physician reach beyond owned clinics. (Link)
  14. Frazier Healthcare Partners portfolio company LUX Infusion has acquired Infuse IQ, a Cody, Wyoming-headquartered independent infusion therapy provider operating six ambulatory infusion centers. LUX Infusion, the Frazier Healthcare Partners-backed platform formerly known as BioMatrix Specialty Infusion Pharmacy, has added Infuse IQ in its latest tuck-in. Terms were undisclosed. The sponsor’s thesis is site-of-care migration: as payers push infusion out of hospital outpatient departments, LUX is assembling an omnichannel network spanning home infusion and ambulatory centers, now reaching from Alaska to the Southeast. Infuse IQ contributes six clinics serving more than ten specialties with broad payer acceptance and co-pay assistance programs. CEO Brian Zweben cited LUX’s clinician-led model and technology investment as the fit; this follows recent Northeast Infusion Therapy and First Choice deals. (Link)
  15. Versant Diagnostics has acquired American Dermatopathology Laboratory, LLC, a dermatopathology practice based in Centerville, Ohio, and welcomed dermatopathologist H. Nicholas Shamma, MD. Versant Diagnostics, a Grapevine, Texas independent physician services company, has acquired Ohio-based American Dermatopathology Laboratory, extending a national roll-up of subspecialty anatomic pathology practices. Financial terms were not disclosed and both parties are private. The Ohio practice folds into Versant DermPath, the company’s dermatopathology-focused entity, with Dr. Shamma joining as an integral partner. CEO Jim Billington positioned the transaction as building one of the country’s strongest dermatopathologist networks and expanding specialist access. The deal follows Versant’s 2025 expansion into Georgia and reflects a consolidation model that pairs digital pathology infrastructure with physician equity participation. (Link)
  16. Gastro Health has finalized a partnership with Center for Advanced Gastroenterology, a four-physician Central Florida practice. Gastro Health, a national single-specialty digestive and liver health group, has added Center for Advanced Gastroenterology, which operates offices in Maitland and Lake Nona with four board-certified gastroenterologists and two advanced practice providers. Financial terms were undisclosed and both parties are private. CEO Alan Oliver framed the strategy as extending the network by collaborating with high-quality practices in existing markets, and the platform explicitly characterises the transaction as an acquisition milestone in its growth plan. The eighth Orlando-area deal reflects a density-first consolidation approach that concentrates referral flow and ambulatory endoscopy volume within defined geographies. (Link)
  17. Unite Us has acquired Vircho Health, a performance, quality and financial analytics platform for community care networks, strengthening its health and community care infrastructure. Unite Us, the social care coordination network, has acquired Vircho Health including its full team led by co-founders Craig Manson and Evan Jones. Financial terms were undisclosed and both companies are private. The deal responds to a funding shift in social determinants of health, where government payers, health plans and foundations increasingly demand proof of outcomes and quantifiable financial return rather than closed-loop referral confirmation alone. Unite Us brings a thirteen-year dataset of nearly 125 million care connections; Vircho adds dollar-level expenditure tracking and per-organisation performance reporting. Vircho tools already run alongside Unite Us in North Carolina through Impact Health. (Link)
  18. Ascend Learning has acquired Teaching Assignment Management System (TAMS), a cloud-based faculty workload platform built at Duke University. Ascend Learning, a healthcare and learning technology company, has acquired TAMS, used by more than 70 institutions including Johns Hopkins, Texas A&M and Marquette. Terms were undisclosed. CEO Lissy Hu framed the rationale as owning the full continuum from faculty planning through student outcomes, building on ATI Nursing Education’s penetration of more than 60% of U.S. nursing schools. The strategic value is cross-sell into an installed base at a moment when nursing programs face faculty shortages and enrolment pressure. Founder David Parrish cited Ascend’s distribution reach as the deal driver; the platform replaces spreadsheet-based assignment and workload processes. (Link)
  19. Copley Equity Partners portfolio company FMG Leading has acquired Washington, D.C.-based market intelligence and strategic advisory firm BroadBranch Advisors, adding competitive and customer intelligence capabilities to its healthcare advisory platform. FMG Leading, a Philadelphia-based strategic advisory firm founded in 1984 and backed by Copley Equity Partners since 2022, closed its purchase of BroadBranch Advisors effective July 31, 2026. Terms were undisclosed and both firms are privately held. The sponsor thesis is capability stacking rather than scale: FMG advises investor-backed healthcare executives on growth and value creation, and BroadBranch contributes an “outside-in” competitive and customer intelligence practice, combining market insights with organisational health data on one platform. CEO and Chairman Matt Brubaker cited rising client demand for faster translation of forward-looking intelligence into action. BroadBranch Managing Partner Courtney Matson continues with the combined business. (Link)
  20. Tortuga Growth Partners has made a strategic investment in Advanced eClinical Training, an online healthcare certification and workforce development provider, through Tortuga Growth Partners Fund I, L.P. Tortuga Growth Partners, a New York private investment firm built around disciplined buy-and-build, has invested in Advanced eClinical Training out of its debut fund, extending the build-out of its healthcare vertical. Terms were undisclosed. Managing Member Ashray Prasad framed the thesis as backing founders addressing large, enduring problems with structural tailwinds, citing an American Hospital Association projection of a 3.2 million-worker healthcare shortage this year. Senior Managing Director Walt Vester will help scale the platform. Tortuga has assembled a board and advisory group including operating partners Michael O’Neil, who becomes executive chair, Vester and Marty DeMonte alongside co-founders Shay and Shabnam Safarzadeh. (Link)
  21. GreyLion and Vestar Capital Partners portfolio company 360training.com, Inc. has acquired select assets of seven San Antonio-based compliance training brands, including American Health Training and National OSHA Foundation. 360training, an Austin-based regulated online training platform owned by GreyLion and Vestar Capital Partners, has executed another add-on in a rapid buy-and-build cadence that already includes ACLS Medical Training, Canadian Food Safety Group and the On The Fly brands in 2026 alone. Terms were undisclosed. The acquired portfolio spans healthcare, OSHA and workplace safety, food handling, forklift operations, hazardous materials, defensive driving and transportation safety, broadening the sponsors’ multi-industry compliance footprint across the United States and Canada. The strategy is consolidation of fragmented, mandatory-certification niches where regulatory complexity supports recurring, non-discretionary demand. (Link)
  22. Lee Health has acquired Gardner Orthopedics, a Fort Myers orthopedic practice, expanding the nonprofit system’s musculoskeletal service line across Southwest Florida. Lee Health, a Southwest Florida nonprofit health system, has acquired Gardner Orthopedics, absorbing all 75 employees including five physicians alongside nurses, physical therapists and medical assistants. Financial terms were not disclosed; as a nonprofit system acquisition of a physician practice, no sponsor capital is involved. Kris Fay, Chief Administrative Officer of LPG and Ambulatory Care, positioned the deal as expanding access to orthopedic and musculoskeletal care. The Winkler Avenue facility remains operational, strengthening outpatient footprint. The transaction supports the Lee Health Musculoskeletal Institute build-out at a time of sustained population growth in the region. (Link)
  23. Philips International has completed the acquisition of the healthcare consulting, technology and recruiting businesses of The Nash Group, Inc., Advance Solutions International, Inc. and Nursing Advisory Services LLC. Philips International, a Great Neck, New York privately held investment company has closed its purchase of the Nash healthcare businesses. Financial terms were undisclosed. Adrian Miller, Managing Director of Corporate M&A at Philips International, cited the platform’s expertise, longstanding customer relationships and differentiated workforce solutions, and said the buyer will invest in people, technology, business development capability and operating infrastructure. Established in 1992, The Nash Group serves hospitals across staffing optimisation, acuity and workload analysis, operational performance improvement, hospital technology, and domestic and international nurse recruitment. (Link)
  24. Codis completes acquisition of Catalent’s Nottingham, UK facility Codis, a global CDMO specializing in spray drying and amorphous solid dispersions, has closed its acquisition of Catalent’s Nottingham, UK facility. The site adds oral solid dose development, clinical supply and small-scale commercial manufacturing capabilities, complementing Codis’ commercial-scale spray drying operations in Haverhill. The combination creates an integrated European pathway from early development through commercial intermediates and finished dose forms. Financial terms were not disclosed. (Link)
  25. Nexa Equity portfolio company Facility Grid has acquired PingCx, an autonomous commissioning platform for building automation systems, and launched a unified building lifecycle software platform. Facility Grid, a Waltham, Massachusetts commissioning and operational readiness software provider backed by San Francisco-based growth equity firm Nexa Equity, has acquired PingCx. Terms were undisclosed. Nexa manages more than $1 billion in assets and runs a concentrated investment approach pairing investors with operators. The acquisition converts Facility Grid from a point commissioning tool into a three-product platform, with PingCx becoming FG Validate alongside FG Construct and FG Sustain, the latter launching in September. CEO Daniel Russo positioned the strategy around owning the system of record across a building’s full life rather than only its construction phase. (Link)
  26. Sheridan Capital Partners has completed its investment in Carolina Components Group, a Durham, North Carolina supplier of custom-engineered bioprocessing assemblies to biopharmaceutical manufacturers. Sheridan Capital Partners, a healthcare-dedicated private equity firm investing $30 million to $150 million per manufacturing deal out of its $575 million Fund III, has closed a private investment in Carolina Components Group. Financial terms were undisclosed. Partner Michael Bernard described CCG as the output of a multi-year thesis in the pharmaceutical manufacturing supply chain, with the deal led alongside Sean Dempsey and Conor Kolstad. Founder John Cooling and other leaders retain meaningful ownership and Cooling joins the board, while Maurice Phelan, formerly President of Sartorius North America, becomes CEO. CCG serves over 250 biopharma and CDMO customers. (Link)
  27. Neuronetics, Inc. (NASD: STIM) and second-largest shareholder Jorey Chernett of Pointillist Family Office have reached an agreement establishing a path to board representation, with largest holder Madryn Asset Management, LP reaffirming its support. Neuronetics (NASDAQ: STIM) has resolved a months-long campaign by Jorey Chernett, whose Pointillist Family Office holds 14.12% of shares outstanding and 10,588,988 shares with sole voting and dispositive power. Chernett had criticised chronic underperformance since the $45 million Greenbrook TMS acquisition in late 2024 and pushed for a sale of the TMS device business; the company is not pursuing that route. Under the understanding, Chernett may recommend a new board appointee and has affirmed comfort with the capital position. Madryn Asset Management Managing Partner Avi Amin, also a director, reaffirmed conviction in the platform. (Link)
  28. iSpecimen Inc. (NASD: ISPC) has closed a $5.0 million public offering of common stock and pre-funded warrants, with participating investors subscribing for 996,231 shares and warrants over up to 2,849,923 additional shares. iSpecimen (NASDAQ: ISPC), an online marketplace connecting biospecimen researchers with healthcare specimen providers, priced the offering on August 6 and closed August 7, 2026 for gross proceeds of approximately $5 million. The heavy pre-funded warrant component relative to common stock indicates investors managing beneficial ownership thresholds, a common structure for micro-cap issuers with concentrated demand. Proceeds are earmarked for repayment of outstanding liabilities, potential acquisitions and investments, marketing initiatives, general corporate purposes and working capital. The registration statement was filed June 24, 2026 and declared effective July 30, 2026. (Link)
  29. Health Catalyst, Inc. (NASD: HCAT) has completed the sale of its Vitalware mid-revenue-cycle business to Med-Metrix LLC for $147 million in cash and used the proceeds to fully retire its credit facility. Health Catalyst (NASDAQ: HCAT) closed the divestiture of Vitalware to Med-Metrix on July 31, 2026 for $147 million of total cash consideration, subject to customary adjustments. Proceeds plus balance-sheet cash repaid and terminated all obligations under the company’s credit facility, eliminating roughly $19 million of annualised GAAP interest expense based on first-half 2026 figures. The transaction is a balance-sheet reset as much as a portfolio move: management framed the strengthened capital position as funding a narrower roadmap around cost management, clinical quality and consumer loyalty intelligence products. Med-Metrix gains coding compliance, chargemaster, charge capture and price transparency assets. (Link)
  30. Solventum Corporation (NYSE: SOLV) has reported second quarter 2026 results and announced plans to separate its Health Information Systems division, following the earlier divestiture of its Purification and Filtration business. Solventum (NYSE: SOLV) posted $2.2 billion of second quarter sales with 9.5% organic growth against 2.2% reported growth, and raised full-year guidance. The capital-structure story is the more investor-relevant one: net debt has fallen $2.6 billion since separation from 3M (NYSE: MMM) to $4.7 billion, funded largely by net proceeds from the September 2025 sale of Purification and Filtration. Management then announced its intention to spin off Health Information Systems, a second act of portfolio separation for a company itself created by spin-off. Shares rose 3.4% after hours to $90.47, surpassing the prior 52-week high. (Link)
  31. Care Options for Kids has completed the rebranding of its Chicago-area affiliate Health Force under the Care Options for Kids name, unifying its Illinois pediatric home care identity. Care Options for Kids, a national pediatric home healthcare provider, announced that Health Force has formally transitioned to the Care Options for Kids brand, establishing a single identity in Illinois. No new transaction, consideration or investor was disclosed: Health Force was already part of the platform, making this an integration and branding milestone rather than a fresh acquisition. Operating in the Chicago area since 1993, the business continues providing one-to-one pediatric care at home, in schools and in communities, with local clinicians gaining access to the platform’s shared clinical resources and standardised processes. (Link)

Venture Deals and Other

  1. Standard Capital has led a $15 million Series A in San Francisco-based Andromeda Surgical, with participation from Y Combinator, Vox Capital, Lingotto Innovation, Alumni Ventures, WestWave Capital, Pioneer Fund and Phaze Ventures. Standard Capital led the $15 million round for Andromeda Surgical, taking total funding to $30 million as the autonomous surgery company moves from clinical validation to commercial launch. Pioneer Fund has now backed the company twice, starting at seed, and Oman-based Phaze Ventures participates from its earlier investment. Investors are underwriting an endourology-first thesis: the system has performed HoLEP procedures in more than 40 patients across three countries, with enucleation times as fast as 30 minutes against a published average near 90. Andromeda holds clearance in Canada and New Zealand, with first commercial installations expected within two months. (Link)
  2. Strategic investors NDS Corporation and Aimed Bio Inc. have backed Inocras Inc.’s oversubscribed $31 million Series B-3 alongside new investors IMM Investment, Korea Investment & Securities, LoftyRock Investment, DT& Investment, Woori Investment & Securities and Shinhan Securities, with existing holders DSC Investment, Dunamu & Partners and InterVest participating. The oversubscribed Series B-3 takes San Diego-based Inocras to approximately $100 million of total funding. The investor syndicate is notably Korea-weighted, reflecting the company’s origins as a KAIST spinout and its installed base across Asia. Capital funds U.S. commercial and operational build-out of its CLIA/CAP-certified whole-genome sequencing and automated bioinformatics infrastructure. Investors are backing demonstrated traction rather than early-stage risk: the platform is used by more than 100 cancer institutions, supports roughly 30 South Korean hospitals and holds meaningful commercial presence in Hong Kong. Strategic participation from Aimed Bio follows a July equity investment and joint research agreement. (Link)
  3. UMass Memorial Health has led the $10 million first close of Wellinks’ Series B round, with participation from existing inside investors. UMass Memorial Health, a strategic rather than financial investor, anchored the $10 million first tranche for New Haven-based Wellinks, deepening a multiyear commercial relationship that began with a 2022 UMass Chan research collaboration and a 2024 virtual pulmonary rehabilitation partnership. The investment is underwritten by outcomes data: the joint Healthy at Home study showed participants with more than 60% lower odds of 30-day COPD readmission. Proceeds fund commercial expansion into rural and underserved markets, advance the predictive analytics engine behind the FDA-cleared Spire remote monitoring system, and extend the care model into congestive heart failure. Inside investors supported the round. (Link)
  4. Boost VC, Cleo Capital, Manna Ventures and Profluent Capital have backed SkinBit’s $6 million pre-seed round, joined by Lyft, Inc. (NASD: LYFT) co-founder Logan Green and nine board-certified dermatologists. The $6 million pre-seed for Los Angeles-based SkinBit is an unusually well-syndicated first institutional round, pairing four venture funds with an operator angel in Lyft (NASDAQ: LYFT) co-founder Logan Green, who joins the board, and nine practising dermatologists whose participation doubles as clinical distribution. Investors are funding a data-asset thesis rather than a device: proceeds deploy full-body scanners into med spas, longevity clinics and dermatology practices, targeting three locations in 2026 and fifteen by end-2027, with each scan compounding a longitudinal, patient-owned imaging record. Founded 2023 by Jonathan Benassaya, with Stanford and OHSU dermatology leadership attached. (Link)
  5. 4DMedical Limited (ASX: 4DX) has made a $3.4 million strategic investment in Seattle-based RevealDx and signed a global distribution agreement for the RevealAI-Lung nodule characterisation software. 4DMedical (ASX: 4DX) is combining a $3.4 million equity investment with exclusive distribution rights across the United States, Europe, Australia and New Zealand, a structure that gives the listed acquirer optionality on RevealDx without full consolidation. The investment follows 4DMedical’s acquisition of Austrian chest CT company contextflow, into whose platform RevealAI-Lung is already integrated and deployed at European clinical sites. The commercial case rests on reimbursement and regulatory position: FDA clearance, European MDR certification, Australian TGA approval and U.S. Medicare coverage under CPT codes 0721T and 0722T, with validation across more than 1,500 patients. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update May 11th, 2026

LECO_Weekly-Healthcare-News_5-11-2026Download
  1. Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease Angelini Pharma S.p.A., an international pharmaceutical company and part of Italy’s Angelini Industries Group, entered into a definitive agreement to acquire Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), a Coral Gables, FL-based commercial-stage biopharmaceutical company focused on rare and difficult-to-treat diseases, in an all-cash transaction valued at approximately $4.1 billion or $31.50 per share. The deal, announced May 7, 2026, represents a premium to Catalyst’s recent trading prices and will expand Angelini Pharma’s U.S. market presence and rare-disease portfolio, particularly in brain health and neurological conditions. Closing is expected in the third quarter of 2026, subject to Catalyst stockholder approval, regulatory clearances, and other customary conditions. (Link)
  2. Roche Holding AG (SIX: RO, ROP; OTCQX: RHHBY), the Swiss pharmaceutical and diagnostics giant, entered into a definitive merger agreement to acquire PathAI, a Boston-based AI-powered digital pathology company, for USD 750 million upfront plus up to USD 300 million in milestone payments, valuing the deal at up to USD 1.05 billion. Roche (SIX: RO, ROP; OTCQX: RHHBY) has signed a definitive merger agreement to acquire Boston-based digital pathology firm PathAI. Under the terms of the agreement, Roche will pay a purchase price of USD 750 million upfront and additional milestone payments of up to USD 300 million, bringing total potential consideration to USD 1.05 billion. Roche has partnered with the company since 2021, expanding their agreement in 2024 to include the development of AI-enabled companion diagnostic algorithms. Roche Diagnostics will absorb PathAI as an operating unit after closing expected in H2 2026, pending regulatory clearance, accelerating Roche’s AI-powered diagnostics capabilities. (Link)
  3. Cross Country Healthcare, Inc. (NASD: CCRN), a Boca Raton-based technology-driven healthcare workforce solutions company, entered into a definitive agreement to be acquired by growth-oriented private equity firm Knox Lane in an all-cash transaction valued at approximately $437 million, or $13.25 per share. Cross Country Healthcare (NASDAQ: CCRN) has signed a definitive agreement to be taken private by Knox Lane, a growth-oriented investment firm, in an all-cash transaction valued at $437 million, or $13.25 per share. The price represents a premium of approximately 31% to CCRN’s closing price on May 6, 2026, and a 45% premium to its 90-day volume-weighted average trading price. Knox Lane is a private equity firm with $3.5 billion in assets under management. Upon completion, Cross Country Healthcare will become a privately held platform company in Knox Lane’s portfolio and will cease trading on Nasdaq, with closing expected in Q3 2026.  (Link)
  4. Sanford Health, a Sioux Falls, South Dakota-based nonprofit rural health system, and North Memorial Health, a Twin Cities-based Minnesota nonprofit health system, signed a definitive agreement to combine into a single nonprofit organization, supported by a planned $600 million investment. Sanford Health and North Memorial Health have signed a definitive agreement to combine into a single nonprofit health system. The transaction includes a $600 million investment in Twin Cities services. Sanford’s most recent annual revenue was nearly $11.7 billion in 2025, which reflects its merger with Marshfield Clinic Health System in Wisconsin. Sanford Health President and CEO Bill Gassen will continue to serve as president and chief executive officer of the combined organization. The partnership is expected to close sometime this year, subject to completion of regulatory processes and other customary closing conditions. (Link)
  5. The University of Pittsburgh Medical Center (UPMC), a Pittsburgh-headquartered nonprofit health care provider and insurer, and CommonSpirit Health, one of the nation’s largest nonprofit Catholic healthcare organizations, signed a definitive agreement transferring ownership of Steubenville, Ohio-based Trinity Health System to UPMC. UPMC and CommonSpirit Health have signed a definitive agreement transferring ownership of Trinity Health System to UPMC. The transfer includes Trinity West, Trinity East, Trinity St. Clairsville Neighborhood Hospital, Trinity Twin City Medical Center, and associated clinics, to UPMC. The transaction is expected to be completed in Fall 2026, pending regulatory review and customary closing conditions. The deal will allow UPMC to expand into the Midwest from its foothold in the mid-Atlantic. Financial terms were not disclosed. The deal marks UPMC’s first expansion into Ohio while supporting CommonSpirit’s multiyear asset-divestiture turnaround strategy. (Link)
  6. agilon health, inc. (NYSE: AGL), an Austin, TX-based value-based care platform partnering with primary care physicians on Medicare Advantage, saw its stock surge after delivering Q1 2026 revenue of $1.42 billion and GAAP EPS of $1.80, prompting upgrades from Deutsche Bank and Jefferies. agilon health (NYSE: AGL) shares surged sharply following a Q1 2026 earnings beat. Revenue came in at $1.42 billion versus analyst estimates of $1.38 billion, EPS (GAAP) of $1.80 crushed the consensus of $0.83, and Adjusted EBITDA of $53.84 million beat estimates of $36.15 million by nearly 49%. Deutsche Bank upgraded agilon health’s stock rating to Buy from Hold, raising its price target to $49.00, while Jefferies also upgraded the stock to Buy. For the full year, the company raised its 2026 Adjusted EBITDA guidance to $10–$40 million, with new CEO Tim O’Rourke commencing leadership. (Link)
  7. Addus Enters Indiana With HomeCourt Acquisition, Lines Up Second Deal Addus HomeCare Corporation (NASDAQ: ADUS), a Frisco, Texas-based provider of home and community-based personal care services, acquired HomeCourt Home Care, a Fort Wayne, Indiana-based non-medical home care agency. Addus HomeCare has entered the Indiana market through the acquisition of HomeCourt Home Care. The deal adds approximately $9.8 million in annualized revenue and expands Addus’ footprint into the Midwest with a strong regional provider of in-home personal care and supportive services for elderly and disabled clients. The transaction closed on May 1, 2026 and marks Addus’ continued geographic expansion strategy in the home-care sector. Financial terms were not disclosed. (Link)
  8. HealthVerity, Inc., a Philadelphia-based leader in privacy-protected real-world data exchange and patient identity solutions, entered into a definitive agreement to acquire Symphony Health Solutions Corporation, a commercial healthcare data and analytics business formerly part of ICON plc (NASDAQ: ICLR). HealthVerity has announced the acquisition of Symphony Health to combine its clinical data depth with Symphony’s commercial insights, creating a unified, AI-ready platform for life sciences, payers, and government entities. The transaction, announced on May 5, 2026, is expected to close in May 2026 subject to customary closing conditions. Financial terms were not disclosed. (Link)
  9. Elsevier completes acquisition of Mytonomy and introduces comprehensive end to end patient engagement solutions for healthcare providers. Elsevier, a global leader in scientific publishing and health information solutions (part of RELX plc), completed the acquisition of Mytonomy, Inc., a Washington, D.C.-based provider of cloud-based video patient engagement and education platforms for hospitals and health systems. Elsevier has completed the acquisition of Mytonomy to integrate its clinical content libraries with Mytonomy’s video-first patient engagement platform, creating end-to-end solutions that improve adherence, reduce readmissions, and support value-based care across the care continuum. The deal, closed on May 5, 2026, combines Elsevier’s trusted evidence-based content with Mytonomy’s HIPAA-compliant, personalized video and interactive tools already deployed at more than 300 U.S. healthcare organizations. Financial terms were not disclosed. (Link)
  10. CQ Medical, the Avondale, Pennsylvania-based global leader in radiotherapy positioning solutions formed in 2022 through the combination of CIVCO Radiotherapy and Qfix, acquired .decimal, a Sanford, Florida-based precision manufacturer of patient-specific radiotherapy beam-shaping devices. CQ Medical has acquired .decimal to expand its patient-specific cancer treatment portfolio. CQ Medical was formed in 2022 through the combination of CIVCO Radiotherapy and Qfix, bringing together decades of expertise in essential radiation therapy positioning and immobilization solutions. Serving the radiotherapy clinical community for more than 40 years, .decimal is a trusted partner known for its rapid production of customized, patient-specific devices—typically manufactured and shipped within 1–2 days of order receipt. To date, the company has delivered over 500,000 patient-specific treatment devices, and actively serves more than 900 cancer centers across the United States. Financial terms were not disclosed. (Link)
  11. Med Tech Solutions (MTS), a Valencia, California-based managed healthcare IT services provider and portfolio company of Silversmith Capital Partners, acquired Avarion (formerly Huntzinger Management Group), a two-time Best in KLAS healthcare IT advisory firm, to span the full care continuum. Silversmith Capital Partners-backed Med Tech Solutions has acquired Avarion to strengthen its managed services platform. Med Tech Solutions, a provider of managed healthcare IT services and a portfolio company of Silversmith Capital Partners, acquired Avarion, a healthcare IT advisory firm serving hospitals, health systems and care networks. The combination unites MTS’ EHR managed services, application support, and technology infrastructure expertise with Avarion’s deep experience in healthcare IT advisory, consulting, and leadership services. Robert Kitts, Avarion’s CEO and founding partner, will report to Mona Abutaleb, CEO of MTS, and lead the company’s strategic advisory and staffing services. Financial terms were not disclosed. (Link)
  12. TimelyCare, a Fort Worth, TX-based virtual care provider for higher education serving nearly 500 campuses nationwide, acquired Alongside, a clinician-designed AI coaching platform trusted by more than 200 schools, to expand its student support model with continuous early-intervention AI coaching. TimelyCare has acquired Alongside, a clinician-designed AI coaching platform for students. Alongside combines evidence-based skill-building with proprietary safety models that detect risk and connect students to additional support when needed. Trusted by nearly 500 campuses across the U.S., TimelyCare combines URAC-accredited clinical standards with a measurement-based approach, while Alongside is trusted by more than 200 schools nationwide. The acquisition expands TimelyCare’s approach beyond traditional points of clinical need, positioning the company to engage a broader student population earlier and more consistently across the care continuum. Financial terms were not disclosed. (Link)
  13. Xpress Wellness, a Goldman Sachs-backed Oklahoma City-based provider of urgent care, virtual primary care, occupational medicine, behavioral health and post-acute services, acquired Midwest Counseling Services, a Wichita, Kansas-based mental health clinic founded in 2022 serving older adults in senior communities. Goldman Sachs-backed Xpress Wellness has acquired Wichita-based Midwest Counseling Services. Founded in 2022, Midwest Counseling Services provides mental health services to older adults living in senior communities through approaches including talk therapy and individual counseling. Xpress Wellness is an Oklahoma City-based provider of urgent care, virtual primary care, occupational medicine, behavioral health and post-acute services across rural and suburban communities. Lisa Harrison, founder of Midwest Counseling Services, now serves as Xpress Wellness’ Director of Operations of Post-Acute overseeing the Kansas market, with the deal expanding the acquirer’s behavioral health footprint in Kansas and adjacent states. (Link)
  14. Pediatrica Health Group, a Miami-based multi-site pediatric primary care platform backed by M33 Growth, acquired the long-established Westchester, Miami-Dade pediatric practice of Dr. Juan Ruiz-Unger to expand equitable access to care amid rising regional population growth. Pediatrica Health Group, backed by Boston-based venture and growth-stage investor M33 Growth, has acquired an additional pediatric practice in the Westchester neighborhood of Miami-Dade County. For over 40 years, Dr. Juan Ruiz-Unger has delivered compassionate, evidence-based care to Westchester families. Roberto Palenzuela, Chief Executive Officer of Pediatrica Health Group, said the acquisition aligns with the company’s goal of supporting physicians who want to expand access while maintaining continuity of care within their communities. Financial terms were not disclosed. The deal continues Pediatrica’s multi-site pediatric primary care roll-up strategy across South Florida. (Link)
  15. SpinLife, a Columbus, Ohio-based omni-channel mobility and home accessibility retailer owned by Brentwood, Tennessee-based Complex Rehab Technology leader Numotion, acquired Triton Medical and opened a new SpinLife retail store in Lady Lake, Florida, expanding its Central Florida footprint. Numotion-owned SpinLife has acquired Triton Medical and launched a new Central Florida retail location. SpinLife, owned by Numotion, said in a May 5 announcement that the acquisition was completed on April 22. The retail location is now operating as SpinLife — Lady Lake and strengthens the company’s presence in central Florida and enhancing service to the growing Lady Lake and The Villages communities. Matt Chesshire, Triton Medical’s founder, will remain at the Lady Lake store as general manager. Numotion acquired SpinLife in 2021. Financial terms were not disclosed. (Link)
  16. Care Advantage, Inc., a Mid-Atlantic-based privately held home care provider, announced the acquisition of First Priority Home Care, a Columbia, South Carolina-based non-medical home care agency, advancing its targeted expansion strategy across the Mid-Atlantic and Southeast. Care Advantage, Inc. has acquired Columbia, South Carolina-based First Priority Home Care. Care Advantage, one of the Mid-Atlantic’s largest privately held home care providers, today announced the acquisition of First Priority Home Care, based in Columbia, South Carolina. This latest transaction marks another step in Care Advantage’s continued expansion into the southern United States. First Priority Home Care is a non-medical home care agency based in Columbia, South Carolina, providing in-home support services to seniors and adults who need assistance. Financial terms of the deal were not disclosed. (Link)
  17. Standard Dental Labs Inc., (OTCQB:TUTH) an Orlando-based publicly traded dental laboratory consolidator, completed the acquisition of BRLIT Dental Laboratory, a Sarasota, Florida-based dental lab founded in 1977, adding approximately $886,000 in annual revenue. Standard Dental Labs Inc. (OTCQB: TUTH) has completed the acquisition of BRLIT Dental Laboratory in Sarasota, Florida. The transaction adds approximately $886,000 in annual revenue to Standard Dental Labs’ existing revenue base of approximately $236,000, bringing the company’s total annualized revenue to more than $1.1 million. The company holds a market capitalization of $6.54 million. BRLIT Dental Laboratory, founded in 1977, has served dentists throughout Florida for nearly five decades, and the acquisition expands the buyer’s footprint along Florida’s Gulf Coast. The company intends to continue pursuing strategic acquisitions in Florida’s dental laboratory industry. (Link)
  18. TopGum Industries Ltd. (TASE: TPGM), an Israel-based global leader in gummy-format dietary supplements, completed the acquisition of the U.S. gummy manufacturing operations of P&L Developments LLC, a Westbury, New York-based pharmaceutical and consumer healthcare CDMO, in a transaction valued at up to USD 35 million. TopGum Industries Ltd. (TASE: TPGM) has completed its acquisition of P&L Developments’ U.S. gummy manufacturing operations. The consideration, funded by TopGum’s existing resources, comprises US$10 million in cash at closing, 1,893,060 shares valued at approximately US$8 million at closing (based on a price of NIS 13 per share), and up to 4,022,751 additional shares (valued at up to US$17 million) as contingent consideration, payable upon achievement of agreed commercial and regulatory milestones.  (Link)
  19. Arete Health Announces Acquisitions of Virginia Rehabilitation & Wellness and Summerville Physical Therapy & Balance for Adults Arete Health, a physician-led multi-specialty practice management platform, acquired Virginia Rehabilitation & Wellness and Summerville Physical Therapy & Balance for Adults, two established physical therapy practices in Virginia. Arete Health has completed the acquisition of two Virginia-based physical therapy practices—Virginia Rehabilitation & Wellness and Summerville Physical Therapy & Balance for Adults—on May 5, 2026. The deals strengthen Arete’s outpatient rehabilitation footprint in the Mid-Atlantic and add specialized orthopedic, sports medicine, and balance therapy services. The combined practices serve several hundred patients weekly across multiple locations. Financial terms were not disclosed. (Link)

Venture Deals and Other

  1. Basata, a Phoenix-based AI company building the operational layer for U.S. healthcare, raised a $21 million Series A led by Basis Set Ventures with participation from Cowboy Ventures, PHX Ventures, Zenda Capital, and Victoria Treyger, bringing total funding to $24.5 million. Basata has closed a $21 million Series A funding round to scale its AI-driven healthcare administrative automation platform. The Series A was led by Basis Set Ventures, with participation from Cowboy Ventures, PHX Ventures, Zenda Capital, and Victoria Treyger. The round brings total funding to $24.5 million. Basis Set Ventures’ Lan Xuezhao led the round, joined by Cowboy Ventures’ Aileen Lee, PHX Ventures, Zenda Capital, and Victoria Treyger. The company has served more than 500,000 patients to date, including 100,000 patients during the past month alone, while working with specialty groups across cardiology, urology, gastroenterology, and ophthalmology. (Link)
  2. Dandelion Health, a New York-based clinical intelligence platform serving life sciences, raised a $14 million Series A led by Healthier Capital with participation from Colle Capital and existing investors Primary Venture Partners, Moxxie Ventures, and Convergent Ventures, to scale its multimodal clinical AI infrastructure. Dandelion Health has secured $14 million in Series A funding. Healthier Capital led the round, with participation from Colle Capital and existing investors Moxxie Ventures, Convergent Ventures and Primary Venture Partners. Built on a network spanning 73 hospitals and more than 15 million patients, Dandelion is unique in its ability to combine structured data — electronic medical records and claims — with unstructured clinical text and raw biological signals including ECG waveforms, echocardiogram videos, radiology imaging, pulmonary function tests, and ultrasound. The Series A financing will be used to expand Dandelion’s pharmaceutical partnerships, scale the company’s data and engineering infrastructure, and grow commercial and scientific teams. (Link)
  3. Enzo Health, a Lehi, Utah-based AI-driven platform for home health and post-acute care launched in 2024, raised a $20 million Series A led by global venture capital firm N47 with participation from existing investors Gradient (a Google-affiliated investment firm), Tandem Ventures, and Rigby Watts, bringing total funding to $26 million. Enzo Health has raised a $20 million Series A funding round. The round was led by N47, bringing the company’s total funding to $26M. Existing investors Gradient, Tandem Ventures, and Rigby Watts also participated. Existing investors Gradient (Palo Alto, a Google-affiliated investment firm), Tandem Ventures (Draper, UT), and Rigby Watts (Millcreek, UT) also participated. Launched in 2024, Enzo Health has grown revenue by more than 40X in twelve months and is now used by organizations that support over 500,000 patients annually. The funds will accelerate expansion into skilled nursing and hospice sectors. (Link)
  4. Travv, a Stillwater, Oklahoma-based AI-native diagnostic platform for veterinary medicine led by founder and CEO Derick Whitley, DVM, DACVP, closed a $1.6 million seed funding round led by Digitalis Ventures with participation from AniVC, to advance its cloud-based veterinary diagnostic platform. Travv has closed a $1.6 million seed funding round. Travv, a Stillwater, OK-based provider of an AI-native diagnostic platform for veterinary medicine, closed a $1.6m seed funding round. The round was led by Digitalis Ventures, with participation from AniVC. The funding will support continued development of Travv’s AI-native diagnostic platform for veterinary medicine, including product expansion, hospital onboarding, commercial growth, and key integrations. Digitalis Ventures backs founders solving critical problems in health. The firm invests in early-stage companies across life sciences, health technology & services, and animal health, while AniVC focuses on early-stage pet companies. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Apr 20th, 2026

LECO_Weekly-Healthcare-News_4-20-2026Download

Healthcare Weekly News and Deals –April 20th, 2026

  1. White House Issues Executive Order to Accelerate Medical Treatments for Serious Mental Illness, with Focus on Psychedelic Research and Patient Access. The White House announced an executive order directing federal agencies to accelerate the research, development, and regulatory review of innovative treatments for serious mental illness, with particular emphasis on psychedelic compounds such as ibogaine for treatment-resistant cases. The order instructs the FDA to issue National Priority Vouchers for Breakthrough Therapy-designated psychedelic drugs, facilitates patient access under the Right to Try Act (including Schedule I substances), and allocates at least $50 million through ARPA-H for state partnerships and clinical trial support. It also calls for enhanced collaboration and data sharing with the VA, plus expedited rescheduling reviews for qualifying substances post-Phase 3. The action aims to address the mental health crisis impacting over 14 million U.S. adults and elevated suicide rates among veterans by promoting treatments offering enduring therapeutic benefits beyond traditional medications. (Link)
  2. McKesson (NYSE: MCK) Signs Agreement with Apollo Funds for $1.25 Billion Strategic Minority Interest in Medical-Surgical Solutions Business. McKesson Corporation (MCK) has entered into an agreement with Apollo Funds for a $1.25 billion investment in convertible preferred equity, representing an approximately 13% minority stake in its Medical-Surgical Solutions (MMS) business at a ~$13 billion enterprise valuation. McKesson will retain majority ownership, operating control, and financial consolidation of the unit. The transaction represents a key milestone in McKesson’s planned separation and future IPO of MMS, which supplies essential products and solutions to non-acute care settings. Apollo’s expertise in carve-outs is expected to support MMS as a well-capitalized standalone company. The deal remains subject to regulatory approvals. (Link)
  3. Global Medical Response (NYSE: GMRS) Files S-1 Registration Statement in Advance of Planned IPO. Global Medical Response (GMR Solutions Inc.) has filed an S-1 registration statement with the SEC for an initial public offering of Class A common stock on the NYSE under the symbol GMRS. The company, the largest U.S. provider of emergency medical services (EMS) and integrated alternate-site care, operates air and ground ambulances across approximately 1,400 counties and serves about 5.5 million patients annually with roughly 34,000 employees. For 2025, GMR reported net revenue of approximately $5.74 billion and Adjusted EBITDA of $1.19 billion. (Link)
  4. Eli Lilly (NYSE: LLY) Acquires Texas ADC Specialist CrossBridge Bio in ~$300 Million Deal to Strengthen Oncology Pipeline. Eli Lilly (LLY) has acquired Houston-based CrossBridge Bio, a preclinical antibody-drug conjugate (ADC) specialist, in a transaction valued at approximately $300 million (mix of upfront and milestones). CrossBridge’s technology, originating from the University of Texas Health Science Center, features advanced linker stability and multi-payload capabilities, with lead TROP2-targeting dual-payload candidate CBB-120 expected to enter the clinic in 2026. The deal further builds on Lilly’s recent ADC acquisitions and internal efforts, enhancing its position in next-generation cancer therapies. (Link)
  5. UCB to Acquire Neurona Therapeutics for Up to $1.15 Billion, Advancing Epilepsy Pipeline with Regenerative Cell Therapy. UCB has agreed to acquire Neurona Therapeutics, gaining its lead asset NRTX-1001, a pluripotent stem cell-derived neuronal cell therapy currently in Phase I/II trials for drug-resistant mesial temporal lobe epilepsy (mTLE). The total transaction value reaches up to $1.15 billion, including $650 million upfront and up to $500 million in potential milestones. The acquisition advances UCB’s leadership in epilepsy by introducing regenerative science approaches aimed at restoring neural circuitry and providing durable seizure control. NRTX-1001 has received FDA RMAT and EMA PRIME designations. The deal is expected to close by the end of Q2 2026, subject to antitrust clearance. (Link)
  6. Organon (NYSE: OGN) Shares Surge Following Reports of Acquisition Interest from Leading Private Equity Firms CVC Capital Partners and TPG. Organon (OGN) witnessed a 25% increase in its stock price amid market reports that CVC Capital Partners and TPG are exploring a potential multi-billion dollar acquisition of the company. The interest from these prominent private equity firms highlights the perceived value in Organon’s diverse portfolio of women’s health products, biosimilars, and established brands. While a formal deal has not been confirmed, the involvement of CVC and TPG suggests a significant investment opportunity in the pharmaceutical space, as financial sponsors look for stable, cash-flow-generative assets. Investors are keeping a close watch on OGN as potential bidding activities could reshape the women’s health sector. (Link)
  7. Avanos Medical, Inc. (NYSE: AVNS) Agrees to $1.272 Billion Acquisition by American Industrial Partners to Transition the Company into Private Ownership. Avanos Medical, Inc. (AVNS) has entered into a definitive agreement to be acquired by affiliates of American Industrial Partners (AIP) for approximately $1.272 billion in an all-cash transaction. AIP’s investment values Avanos at $25.00 per share, representing a significant premium for stockholders. The deal will transition Avanos into a private entity, allowing the company to focus on long-term growth and its innovation roadmap without public market pressures. AIP intends to leverage its deep operational expertise to enhance Avanos’s competitive position in the medical technology sector. The acquisition is expected to close in the second half of 2026, marking a new chapter for the medtech firm. (Link)
  8. Gyde Acquires Benavest, Marking Its Second Deal in Two Weeks as AI-Enabled Health Insurance Brokerage Expands. Gyde, an AI-powered health insurance brokerage platform that launched in January 2026 with $60 million in funding, has acquired Benavest, a national agency specializing in consumer health plans including individual ACA, ICHRA, and Medicare products. The deal follows Gyde’s recent acquisition of Medicare brokerage Avid Health. Benavest brings scalable distribution infrastructure and leadership expertise, which Gyde plans to support with its AI-driven GydeOS platform. No financial terms were disclosed. (Link)
  9. Signant Health, Supported by Financial Sponsors Harvest Partners, Genstar Capital, and Foresite Capital, Enters into a Definitive Agreement to Acquire Ametris. Signant Health has signed a definitive agreement to acquire Ametris, a global leader in digital health solutions, with the backing of private equity firms Harvest Partners, Genstar Capital, and Foresite Capital. This acquisition integrates Ametris’s clinical trial data management and sensor technologies into Signant’s evidence-generation platform. The move is a strategic play by the financial sponsors to consolidate the eClinical technology market, creating a more comprehensive suite of tools for pharmaceutical sponsors. By acquiring Ametris, Signant Health aims to enhance its capabilities in capturing high-quality clinical evidence across virtual, hybrid, and traditional trial models globally. (Link)
  10. BTX Precision, via Financial Sponsors L Squared Capital Partners and CFT Capital Partners, Completes the Strategic Acquisition of Maitland Engineering. BTX Precision has acquired Maitland Engineering to expand its precision manufacturing platform, supported by financial sponsors L Squared Capital Partners and CFT Capital Partners. This acquisition follows a series of strategic moves by BTX, including a recent continuation vehicle led by L Squared and backed by HarbourVest Partners. The investment in Maitland Engineering strengthens BTX Precision’s capabilities in producing complex, high-tolerance components for the medical and aerospace industries. L Squared Capital Partners continues to drive the platform’s buy-and-build strategy, focusing on integrating specialized regional manufacturers to create a dominant, national high-precision engineering entity with significant operational scale. (Link)
  11. CPIhealth, Supported by Financial Sponsor Iron Path Capital, Acquires Midwest Interventional Spine Specialists and Serenity Surgical Center. CPIhealth, a portfolio company of private equity firm Iron Path Capital, has acquired Midwest Interventional Spine Specialists (M.I.S.S.) and Serenity Surgical Center. This acquisition adds two clinical locations and an ambulatory surgery center to CPIhealth’s interventional pain management platform, expanding its presence in the Indiana and Illinois markets. Iron Path Capital’s investment facilitates the integration of five additional physicians and multiple nurse practitioners into the platform. This deal underscores the firm’s strategy of consolidating regional pain management practices to build a multi-state infrastructure capable of delivering advanced, cost-effective interventional spine care through a standardized clinical and administrative model. (Link)
  12. Brado AI Strengthens its Conversational Engagement Platform Through the Strategic Acquisition of ProviderIQ from Hatchleaf. Brado AI has acquired the ProviderIQ asset from Hatchleaf to enhance its precision routing and patient-provider matching capabilities. This acquisition allows Brado AI to integrate clinically informed data and real-world operational workflows into its Conversational Engagement Platform (CEP). By acquiring the technology co-developed with clinicians from Johns Hopkins, Brado AI is investing in more accurate demand-supply alignment for large healthcare systems. The deal reflects Brado AI’s commitment to reducing patient leakage and optimizing provider utilization. The investment highlights a growing trend of AI companies acquiring specialized clinical data tools to provide deeper insights and better ROI for health system partners. (Link)
  13. D2 Solutions Acquires PromodRx to Expand Patient Access and Engagement Technologies for Pharmaceutical and Medical Device Manufacturers. D2 Solutions has completed the acquisition of PromodRx, a cloud-based platform designed to accelerate patient access to prescription medications. This strategic investment expands D2 Solutions’ service offerings in market access, reimbursement support, and patient engagement. By integrating PromodRx’s technology, D2 Solutions strengthens its UltraTouch Verify and Engage platforms, helping pharmaceutical clients navigate complex prior authorization and benefit verification processes. The acquisition is intended to reduce therapy initiation delays and improve patient adherence, positioning D2 Solutions as a more comprehensive commercialization partner in an increasingly complex pricing and policy environment within the life sciences sector. (Link)
  14. H2 Health, a Portfolio Company of Grant Avenue Capital, Expands into Arkansas Through the Strategic Acquisition of Advanced Physical Therapy. H2 Health, backed by private equity firm Grant Avenue Capital, has acquired Advanced Physical Therapy (APT), a practice with six locations in the Little Rock, Arkansas market. This investment marks H2 Health’s expansion into a new state, bringing its total footprint to over 300 clinics across 13 states. Grant Avenue Capital continues to provide the financial resources for H2 Health’s aggressive buy-and-build strategy in the outpatient rehabilitation sector. The acquisition of APT allows H2 Health to leverage its centralized administrative infrastructure to improve operational efficiencies at the local level while expanding access to high-quality physical and occupational therapy services. (Link)
  15. Afterburner Capital and Council Capital Successfully Exit Their Investment in Advanced Care Partners Following an Eight-Year Growth Period. Private equity firms Afterburner Capital and Council Capital have announced the successful exit of their portfolio company, Advanced Care Partners (ACP). During their eight-year investment period, the sponsors helped ACP scale its pediatric and adult private duty nursing services across Georgia and Florida. The exit represents a significant milestone for Afterburner and Council Capital, who focused on professionalizing ACP’s management and clinical infrastructure to drive growth. This transaction highlights the strong investor demand for home-based care platforms that provide high-quality services to medically fragile populations, as financial sponsors seek exits that demonstrate successful clinical and operational scaling in the healthcare services market. (Link)
  16. Stellus Rx, a Portfolio Company of WindRose Health Investors, Acquires Tria Health to Create an Integrated Pharmacist-Led Chronic Care Platform. Stellus Rx, which is backed by WindRose Health Investors, has acquired Tria Health to expand its pharmacist-led pharmacy care management capabilities. This acquisition merges Stellus Rx’s dispensing solutions with Tria Health’s chronic condition support services for self-insured employers. WindRose Health Investors is supporting this combination to create a differentiated platform that reduces the total cost of care through improved medication adherence and clinical outcomes. The investment underscores WindRose’s strategy of backing companies that deliver cost-effective healthcare solutions. The unified entity aims to leverage shared data and clinical expertise to better manage complex patients across the healthcare continuum. (Link)
  17. Mobia Medical (MOBI) Files for a $100 Million Initial Public Offering Led by BofA Securities, J.P. Morgan, and Goldman Sachs to Advance its Vagus Nerve Stimulation Technology. Mobia Medical (MOBI), a developer of neurostimulation devices for chronic stroke recovery, has filed with the SEC to raise up to $100 million in an initial public offering. The IPO process is being led by joint bookrunners BofA Securities, J.P. Morgan, and Goldman Sachs, alongside BTIG and Wolfe | Nomura Alliance. The company, which generated $32 million in revenue in 2025, intends to use the proceeds to expand its commercial organization and fund further R&D for its Vivistim system. This filing signals a major step for the venture-backed company as it transitions into the public markets to capitalize on the $30 billion stroke recovery sector. (Link)

Venture Deals and Other

  1. Avo (AvoMD) Secures $10 Million Series A Funding Led by Noro-Moseley Partners with Participation from AlleyCorp, Las Olas Venture Capital, MedMountain Ventures, Epsilon Health, Scrub Capital, Dunamu & Partners, Mirae Asset Capital, and Futureplay. Avo (formerly AvoMD) has successfully closed a $10 million Series A funding round to advance its AI-powered clinical decision support platform. The round was led by Noro-Moseley Partners, featuring a broad syndicate of investors including AlleyCorp, Las Olas Venture Capital, MedMountain Ventures, Epsilon Health, and Scrub Capital. International support came from Korean firms Dunamu & Partners, Mirae Asset Capital, and Futureplay. The capital will be utilized to scale Avo’s generative AI copilots within major EHR systems, helping clinicians integrate real-time medical knowledge and hospital protocols directly into their digital workflows to improve patient outcomes. (Link)
  2. Bain Capital Life Sciences Backs Beeline Medicines with $300 Million in Capital to Develop Five Clinical Programs Acquired from Bristol Myers Squibb (BMY). Beeline Medicines has emerged from stealth with a massive $300 million investment commitment from Bain Capital Life Sciences. The venture-backed biotech is focused on advancing a portfolio of five clinical-stage programs originally discovered by Bristol Myers Squibb (BMY), targeting autoimmune and inflammatory diseases. This strategic investment allows Beeline to accelerate late-stage clinical development for assets like afimetoran, a TLR7/8 inhibitor. Bain Capital’s funding provides the necessary runway for Beeline to operate as an agile, clinical-stage entity, leveraging established pharmaceutical intellectual property to address significant unmet needs in the immunology and gastrointestinal sectors. (Link)
  3. Pulnovo Medical Announces Oversubscribed $100 Million Financing Round with Strategic Investment from Medtronic. Pulnovo Medical, a pioneer in innovative therapies for pulmonary hypertension, closed an oversubscribed $100 million financing round featuring a strategic investment from Medtronic. The capital will support the advancement of Pulnovo’s clinical programs and commercialization efforts for its pulmonary artery denervation technology. This marks a significant vote of confidence from one of the world’s leading medtech companies in the growing field of interventional pulmonary hypertension treatments. (Link)
  4. Joyful Health Raises $17 Million in Series A Funding Led by CRV with Support from XYZ Venture Capital, Designer Fund, Inflect Capital, and Go Global Ventures. Joyful Health, an AI-driven financial infrastructure provider for the healthcare industry, has secured $17 million in Series A funding. The investment was led by CRV, with participation from XYZ Venture Capital, Designer Fund, Inflect Capital, and Go Global Ventures. The company plans to use this capital to expand its workforce and accelerate the development of its “financial operating system,” which helps healthcare providers automate revenue cycle management and recover unpaid insurance claims. The investors highlighted Joyful Health’s ability to leverage AI to identify processing breakdowns and prioritize high-value recovery opportunities for resource-constrained medical practices. (Link)
  5. Keebler Health Announces $16 Million Series A Investment Led by Flare Capital Partners and Sands Capital to Expand AI Capabilities for Unstructured Clinical Data. Keebler Health has closed a $16 million Series A round led by Flare Capital Partners, with significant participation from Sands Capital. The funding will scale Keebler’s LLM-native platform, which is designed to unlock insights from unstructured clinical documentation—such as provider notes and imaging reports—to improve risk adjustment and value-based care accuracy. Investors noted that Keebler’s technology addresses a critical gap in the market where 80% of patient data remains underutilized. This capital injection will support team expansion and the deployment of real-time clinical insights aimed at enhancing both financial performance and patient outcomes for healthcare systems. (Link)
  6. Worki Secures $2.75 Million in Pre-Seed Funding Led by Founders Fund and Y Combinator to Scale its Healthcare Recruitment and Workforce Management Platform. Healthcare staffing startup Worki has raised $2.75 million in a pre-seed round led by Founders Fund and Y Combinator. The investment targets the growing labor crisis in healthcare by providing a mobile-first platform that simplifies recruitment and scheduling for both providers and facilities. Founders Fund and Y Combinator are backing Worki’s mission to reduce industry reliance on expensive third-party staffing agencies through a more streamlined, automated hiring process. The new capital will be used to enhance the platform’s AI-driven matching capabilities and expand its reach across North American health systems struggling with nurse and technician shortages. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Apr 13th, 2026

LECO_Weekly-Healthcare-News-4-13-2026Download

Healthcare Weekly News and Deals –April 13th, 2026

  1. FunctionHealth, a longevity-focused health tech startup for at-home-accessible lab testing, has acquired mobile healthcare platform Getlabs to bring comprehensive diagnostic services directly to consumers’ homes. Function, a health-tech company focused on proactive wellness, has acquired Getlabs, the leader in nationwide at-home lab draws. This acquisition allows Function to integrate a physical service layer into its digital platform, enabling members to have blood work and other diagnostics performed in the comfort of their homes. The investment is aimed at removing the friction traditionally associated with laboratory testing. By owning the logistical infrastructure of Getlabs, Function can ensure a standardized, high-quality experience for its users, furthering its mission to empower individuals with deep health insights through regular and accessible testing. (Link)
  2. Havencrest Capital Management has completed a majority recapitalization of Offor Health to accelerate the expansion of its clinical delivery model. Havencrest Capital Management, a healthcare-focused private equity firm, has finalized a majority recapitalization of Offor Health. This investment is designed to provide the necessary growth capital for Offor Health to scale its unique model of delivering high-quality clinical care, particularly in the dental and specialized surgical spaces. Havencrest’s involvement will focus on enhancing the company’s operational infrastructure and geographic footprint. The investor views Offor Health as a disruptive force in office-based clinical services, and the capital infusion will support the company’s mission to increase patient access and reduce costs for specialized procedures. (Link)
  3. ESO, backed by financial sponsors Vista Equity Partners and JSL Health Capital, has successfully acquired d2i to accelerate emergency intelligence and improve outcomes across fire, EMS, and health systems. ESO, a leading data and software vendor for emergency medical services (EMS), fire departments, and hospitals, has finalized its acquisition of d2i. The investment, supported by PE firms Vista Equity Partners and JSL Health Capital, aims to integrate d2i’s advanced data analytics and performance management tools into ESO’s ecosystem. This move is designed to provide healthcare professionals with deeper insights into clinical and operational performance. The investors are focused on scaling ESO’s ability to drive better patient outcomes through real-time data intelligence across the continuum of care. (Link)
  4. Council Capital and PMPK have partnered to acquire MedicalServiceQuotes.com to expand their healthcare procurement and analytics platform capabilities. Council Capital, a healthcare-focused private equity firm, alongside PMPK, has acquired MedicalServiceQuotes.com (MSQ). The investment is intended to bolster MSQ’s position as a leading platform for healthcare procurement, providing transparency and efficiency in medical service sourcing. By integrating Council Capital’s deep industry expertise and PMPK’s strategic resources, the company plans to scale its analytics and procurement tools. The investors aim to capitalize on the growing demand for cost-containment solutions in the healthcare sector, helping providers and payers optimize their spend through a more streamlined, data-driven digital marketplace. (Link)
  5. Qualifacts Systems, supported by financial sponsors Warburg Pincus, Martis Capital Management, and Clanton Capital, has completed the acquisition of MethodOne to enhance its behavioral health technology offerings. Qualifacts, a leading provider of electronic health records (EHR) for behavioral health, has expanded its portfolio by acquiring MethodOne. The deal is backed by a powerful consortium of investors including Warburg Pincus, Martis Capital, and Clanton Capital. MethodOne specializes in comprehensive clinic management software for opioid treatment programs. The investors are betting on the consolidation of specialized behavioral health software to create a unified platform that addresses the complex regulatory and clinical needs of addiction treatment providers. This acquisition strengthens Qualifacts’ market position as a premier technology partner in the behavioral health and human services sectors. (Link)
  6. Bioness Medical, via its financial sponsor Accelmed, has acquired the Portable Neuromodulation Stimulator (PoNS) system to bolster its neuro-rehabilitation portfolio. Bioness Medical, a subsidiary supported by the private equity firm Accelmed, has successfully acquired the PoNS system, a non-invasive medical device used in neurological rehabilitation. Accelmed’s strategic investment is aimed at integrating this innovative technology into Bioness’s existing suite of rehabilitation solutions. The acquisition allows Bioness to offer a more comprehensive range of therapies for patients suffering from neurological symptoms due to disease or trauma. Accelmed plans to utilize its expertise in the medical device sector to drive the commercial adoption and clinical validation of the PoNS system in global markets. (Link)
  7. DAS Health, backed by financial sponsor Coalesce Capital, has expanded its national footprint through the acquisition of Prime Care Technologies and Prime Cloud from Prime Holdings. DAS Health, a leader in healthcare IT and management services, has acquired Prime Care Technologies and Prime Cloud. This transaction was facilitated by Coalesce Capital, which provides the strategic funding and guidance for DAS Health’s aggressive expansion strategy. The acquisition integrates advanced cloud hosting and post-acute care technology solutions into DAS Health’s portfolio, enhancing its service offerings for long-term care facilities. Coalesce Capital is focused on building DAS Health into a dominant national provider of healthcare technology solutions, leveraging the synergies between these entities to offer comprehensive, integrated services to a wider range of medical providers. (Link)
  8. Sidekick Therapy Partners, supported by financial sponsors Green Hills Partners and Hillandale Advisors, has acquired Word of Mouth Clinical Associates to broaden its therapy service delivery. Sidekick Therapy Partners, a provider of pediatric therapy services, has acquired Word of Mouth Clinical Associates. The deal is backed by Green Hills Partners and Hillandale Advisors, who are focused on consolidating the fragmented pediatric therapy market. By acquiring Word of Mouth, Sidekick expands its reach and clinical expertise in speech, occupational, and physical therapy. The investors are committed to supporting Sidekick’s growth through operational improvements and strategic bolt-on acquisitions. This move strengthens Sidekick’s ability to provide high-quality, multidisciplinary care to children and families while creating a larger, more efficient regional platform. (Link)
  9. Livtech has successfully acquired Alora Healthcare Systems to integrate advanced home health software into its technology ecosystem. Livtech, a prominent player in healthcare technology, has announced the acquisition of Alora Healthcare Systems. This strategic acquisition focuses on Alora’s specialized software solutions for home health agencies. The investment is intended to create a more robust, end-to-end platform for home-based care providers, streamlining clinical documentation, scheduling, and billing. By integrating Alora’s technology, Livtech aims to provide a seamless user experience for healthcare professionals operating outside of traditional hospital settings. The acquisition reflects the increasing investment interest in home health technology as the industry shifts toward decentralized, patient-centric care models. (Link)
  10. Vertex Pharmaceuticals (NASD: VRTX) has entered into a definitive agreement to acquire Alpine Immune Sciences (NASD: ALPN) for approximately $4.9 billion to bolster its immunology pipeline. Vertex Pharmaceuticals is set to acquire Alpine Immune Sciences in an all-cash deal, significantly expanding its presence in the immunology and immunotherapy space. The acquisition centers on Alpine’s lead candidate, povetacicept, a potential best-in-class treatment for various autoimmune diseases. Vertex is utilizing its strong balance sheet to invest in high-potential late-stage clinical assets that complement its existing focus on serious diseases. This multi-billion dollar investment underscores Vertex’s strategy of diversifying beyond cystic fibrosis and acquiring innovative platforms that can address significant unmet medical needs in the protein engineering and immunology sectors. (Link)
  11. MKH Capital Partners has acquired Haven Health Management to provide growth capital for its 22 treatment locations across the United States. MKH Capital Partners, a family-backed private equity firm, has completed the acquisition of Haven Health Management. The investment provides significant growth capital to support Haven Health’s operations across its 22 addiction and mental health treatment facilities. MKH Capital Partners intends to use its resources to expand Haven Health’s geographic footprint and enhance its clinical services. The investor sees a substantial opportunity in the behavioral health sector, focusing on improving patient access to evidence-based treatment for substance use disorders. This deal highlights the continued interest of private equity in scaling established behavioral health platforms. (Link)
  12. Gilead Sciences, Inc. (NASD: GILD) has announced the acquisition of Tubulis to add a next-generation antibody-drug conjugate (ADC) platform to its oncology pipeline. Gilead Sciences is acquiring Tubulis to gain access to its proprietary ADC technologies, which are designed to create more stable and effective cancer therapies. This strategic investment is part of Gilead’s ongoing effort to diversify its portfolio into oncology and become a leader in targeted cancer treatments. The acquisition includes Tubulis’s diverse pipeline of ADC candidates and its innovative conjugation platforms. Gilead intends to leverage its extensive clinical development and commercialization expertise to accelerate the progress of Tubulis’s candidates, further strengthening its position in the rapidly evolving and highly competitive ADC market. (Link)
  13. BPOC has completed the sale of Midwest Products Engineering (MPE), marking the conclusion of a successful investment period for the private equity firm. BPOC, a healthcare-focused private equity firm, has finalized the sale of Midwest Products Engineering (MPE). During BPOC’s ownership, MPE expanded its capabilities as a leading design and manufacturing partner for medical device OEMs. The firm’s investment supported MPE’s growth through operational enhancements and strategic initiatives, positioning it as a critical supplier in the medical equipment market. This exit demonstrates BPOC’s ability to build value within the medical manufacturing sector. While the buyer was not disclosed, the sale highlights the strong demand for specialized manufacturing firms that serve the high-growth medical device industry. (Link)
  14. Response BPO has joined Carenet Health to exponentially grow its U.S. healthcare impact through expanded operations in South Africa. Carenet Health, a provider of 24/7 healthcare engagement and clinical solutions, has acquired Response BPO. This investment is strategically aimed at leveraging Response BPO’s operational strength in South Africa to enhance Carenet Health’s service delivery for U.S.-based healthcare organizations. The acquisition allows Carenet to offer more cost-effective and scalable engagement solutions, including clinical support and member services. By integrating Response BPO, Carenet Health strengthens its global delivery model, ensuring high-quality, continuous support for its clients while expanding its international footprint in the competitive business process outsourcing market within the healthcare sector. (Link)
  15. Telcor has acquired Sample Healthcare to lead an AI-driven transformation of revenue cycle operations for healthcare providers. Telcor, a leader in laboratory revenue cycle management (RCM) and point-of-care testing software, has acquired Sample Healthcare. This investment is focused on integrating Sample Healthcare’s AI capabilities into Telcor’s existing RCM platform. The goal is to automate complex billing processes, reduce denials, and improve the financial performance of laboratories and health systems. The investors believe that applying AI to revenue cycle operations will significantly increase efficiency and accuracy in healthcare billing. This acquisition reinforces Telcor’s position as an innovator in the RCM space, providing its clients with advanced tools to navigate the complexities of healthcare reimbursement. (Link)
  16. Blackstone and TPG Capital have completed the multi-billion dollar acquisition of medical technology leader Hologic, Inc. (NASD: HOLX). Private equity giants Blackstone and TPG have finalized their acquisition of Hologic, a prominent developer of diagnostic products and medical imaging systems. This strategic move aims to leverage Hologic’s market leadership in women’s health and surgical products to drive further innovation and global expansion. The investors plan to support the company’s R&D initiatives and enhance its operational capabilities through their extensive network and capital resources. This acquisition reflects the ongoing interest of top-tier private equity firms in high-performing medical technology assets with steady revenue streams and significant growth potential in the global diagnostics market. (Link)
  17. Seaport Therapeutics, a PureTech Health (LSE: PRTC) founded entity, has filed for a U.S. Initial Public Offering (IPO) to fund the development of its neuropsychiatric pipeline. Seaport Therapeutics, established by the biotherapeutics company PureTech Health, has officially filed for an IPO in the United States. The company is focused on advancing a pipeline of novel neuropsychiatric medicines using its proprietary Glyph platform, which is designed to enhance the oral bioavailability of drugs. The IPO proceeds are intended to fund clinical trials and further research into treatments for depression, anxiety, and other central nervous system disorders. This move marks a significant milestone for Seaport and its founding investors, as they seek to transition from a venture-backed entity to a public company to access broader capital markets for long-term growth. (Link)
  18. APM Human Services International Limited (ASX: APM) has acquired WorkCare to expand its occupational health and workforce wellness solutions across the global health and human services market WorkCare, a leading provider of occupational health and incident management services, has been acquired by APM Human Services International Limited (ASX: APM). This strategic acquisition allows APM to significantly bolster its “Health and Wellbeing” service vertical, integrating WorkCare’s clinical expertise in medical surveillance, onsite clinics, and telehealth. The investment is focused on scaling WorkCare’s delivery model across the United States and international markets, leveraging APM’s global infrastructure. The deal reflects the investor’s objective to address the increasing demand for integrated, data-driven employee health solutions that reduce workplace injuries and improve organizational productivity on a global scale. (Link)

Venture Deals and Other

  1. Chapter has raised $100 million in a new funding round led by Addition and NFX to simplify the Medicare enrollment process for seniors. Chapter, a technology-driven Medicare advisor, has secured $100 million in growth capital to expand its platform. The round was led by venture capital firms Addition and NFX, with participation from other existing investors. This significant investment will be used to enhance Chapter’s proprietary technology, which helps seniors navigate the complexities of Medicare to find the best-fitting coverage. The investors are backing Chapter’s unique model that searches every available plan, unlike traditional brokers. The capital will also support the hiring of additional advisors and the expansion of the company’s reach to more seniors across the United States. (Link)
  2. HeyDonto has closed a $20 million Seed round at a $200 million valuation to scale Conduit, its innovative dental interoperability exchange platform. HeyDonto, an AI-focused dental technology startup, has raised $20 million in Seed funding from a group of strategic venture investors. The round values the company at $200 million, reflecting strong investor confidence in its Conduit platform. Conduit is designed to solve the long-standing problem of data silos in dentistry by providing a seamless interoperability exchange for patient records and clinical data. The investment will be used to accelerate product development and expand the company’s sales and marketing efforts. The investors aim to position HeyDonto as the central infrastructure for the modern, data-driven dental practice, improving efficiency and patient care. (Link)
  3. SimpliFed has raised over $10 million in an oversubscribed Series A round to expand its maternal health ecosystem and improve access to breastfeeding support. SimpliFed, a maternal health company, has successfully closed a Series A funding round exceeding $10 million. The oversubscribed round included participation from several venture capital firms focused on health-tech and female-founded businesses. SimpliFed provides virtual breastfeeding support and baby feeding guidance, covered by insurance. The new capital will be used to scale the company’s operations, partner with more health plans, and expand its team of clinical experts. Investors are particularly interested in SimpliFed’s ability to provide high-quality, accessible maternal care that improves long-term health outcomes for both mothers and infants while reducing overall healthcare costs. (Link)
  4. Luminai has raised $38 million in a Series B funding round to scale its intelligence platform across health system operations and administrative workflows. Luminai, a company specializing in operational intelligence for healthcare, has secured $38 million in Series B funding. The round was led by prominent venture capital firms looking to capitalize on the automation of healthcare administration. Luminai’s platform uses AI to streamline complex workflows within health systems, reducing the administrative burden on staff and improving operational efficiency. The investment will be used to expand the company’s product features and accelerate its market penetration among large health systems. The investors see Luminai as a key player in solving the staffing shortages and burnout issues currently plaguing the healthcare industry through smart automation. (Link)
  5. Yuzu Health, a next-generation third-party administrator (TPA) providing unified infrastructure for health insurance plans, has raised $35 million in Series A funding. The round was led by General Catalyst and Chemistry, with participation from Anthropic’s Anthology Fund and others. The platform enables customizable plan designs through white-labeled claims processing, payments, and member administration. Proceeds will expand the engineering team and automate manual workflows to scale nationally. Investors see Yuzu Health as a key modernizer of outdated  infrastructure. (Link)
  6. Jimini Health, a clinician-supervised AI platform for behavioral health, has raised $17 million in seed funding led by M13 and Town Hall Ventures. Its Sage assistant integrates into care teams with full clinician oversight and visibility. The capital will support enterprise partnerships, expand clinical capabilities, and deepen EHR integrations. Investors view Jimini Health as a safe, scalable solution to responsibly deploy AI in mental health while addressing risks of unsupervised tools. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Mar 30th, 2026

LECO_Weekly-Healthcare-News_3-30-2026Download
  1. Abbott (NYSE: ABT) Completes Acquisition of Exact Sciences (NASDAQ: EXAS) Abbott (NYSE: ABT) has officially finalized its acquisition of Exact Sciences (NASDAQ: EXAS), a move aimed at bolstering its leadership in the cancer diagnostics and screening market. The integration of Exact Sciences’ flagship Cologuard technology into Abbott’s massive global diagnostics portfolio is expected to drive significant revenue growth and expand access to non-invasive screening tools. Investors are monitoring how this multibillion-dollar deal will impact Abbott’s long-term earnings per share. This strategic consolidation highlights the ongoing trend of medical device giants acquiring specialized biotech innovators to maintain a competitive edge in the preventive healthcare sector. (Link)
  2. Merck (NYSE: MRK) to Acquire Terns Pharmaceuticals (NASDAQ: TERN) for $53 Per Share in Cash Merck (NYSE: MRK) has entered into a definitive agreement to acquire Terns Pharmaceuticals (NASDAQ: TERN) for $53 per share in an all-cash transaction. This acquisition allows Merck to gain control of Terns’ promising pipeline of oncology and metabolic disease treatments, specifically focusing on small-molecule oral therapies. The premium price reflects investor confidence in Terns’ clinical data and the potential for these assets to offset upcoming patent expirations in Merck’s existing portfolio. The deal reinforces Merck’s aggressive M&A strategy to diversify its pipeline through high-value biotech acquisitions that offer immediate technological advantages and long-term market exclusivity. (Link)
  3. Infosys (NYSE: INFY) to Acquire US Firms Optimum Healthcare IT for $465 Million and Stratus for $95 Million Infosys (NYSE: INFY) is significantly expanding its footprint in the United States healthcare sector by acquiring Optimum Healthcare IT for $465 million and Stratus for $95 million. These investments are designed to enhance Infosys’ digital transformation capabilities, specifically within healthcare provider networks and cloud-based medical data management. By bringing these specialized consulting firms under the Infosys umbrella, the company aims to offer more robust, end-to-end IT solutions to American healthcare systems. Investors view this as a strategic deployment of capital to capture the growing demand for digital modernization and data interoperability within the heavily regulated healthcare industry. (Link)
  4. Cencora (NYSE: COR) to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners’ Retina Business Cencora (NYSE: COR), formerly AmerisourceBergen, has announced a deal to acquire the retina-specific business of EyeSouth Partners to expand its Retina Consultants of America (RCA) platform. EyeSouth Partners is backed by Olympus Partners. This acquisition underscores Cencora’s commitment to specialized physician services, particularly in the high-growth ophthalmology sector. By integrating these practices, Cencora enhances its scale in clinical research and specialty distribution, providing a more comprehensive value proposition to manufacturers and patients alike. The investment reflects a broader private equity-style roll-up strategy within the specialty care market, aimed at optimizing operational efficiencies and expanding the company’s geographic reach across the United States. (Link)
  5. Efferent Acquired by Hopper OS via Financial Sponsor GPI Capital Through an LBO Efferent was acquired by Hopper OS on March 24, 2026, through a leveraged buyout (LBO) backed by financial sponsor GPI Capital. This acquisition is intended to integrate Efferent’s specialized technology into Hopper OS’s “intelligent healthcare operating system,” creating a more seamless data environment for providers. GPI Capital’s involvement indicates a strong private equity interest in the healthcare infrastructure space, focusing on companies that can automate clinical workflows. The undisclosed investment will facilitate the scaling of Efferent’s tools, allowing Hopper OS to offer a more robust, AI-enhanced suite of products to its global healthcare clientele. (Link)
  6. HealthTech Solutions Acquired by Health Management Associates via Financial Sponsor BPOC Through an LBO Health Management Associates (HMA) has completed the acquisition of HealthTech Solutions through a leveraged buyout supported by financial sponsor BPOC. The deal, finalized on March 27, 2026, aims to merge HMA’s Medicaid expertise with HealthTech’s advanced technological capabilities. BPOC’s investment highlights the private equity sector’s focus on Medicaid modernization and state-level healthcare IT. By acquiring HealthTech, HMA strengthens its ability to provide technical advisory services to government agencies. The undisclosed transaction is expected to drive growth by enabling HMA to manage complex data systems and improve health outcomes for vulnerable populations through better technology. (Link)
  7. Careflow Receives Growth Investment from Blueprint Equity to Expand Product Platform Careflow has secured an undisclosed amount of development capital from Blueprint Equity as of March 26, 2026. This strategic growth investment is earmarked for the expansion of Careflow’s product platform and the acceleration of its market penetration. Blueprint Equity’s participation marks a significant vote of confidence in Careflow’s software solutions for the healthcare industry. The capital infusion will allow the company to scale its operations and enhance its technological offerings, focusing on improving workflow efficiency for healthcare professionals. This deal exemplifies the active role of private equity in fostering the growth of mid-sized health-tech firms aiming for market leadership. (Link)
  8. Novartis to Acquire Excellergy in Up to $2B Deal to Expand Allergy Pipeline Novartis has agreed to acquire Excellergy, a U.S.-based biotech developing next-generation therapies for allergic diseases, in a deal worth up to $2 billion including milestone payments. The acquisition adds Excellergy’s lead asset, Exl-111, a next-generation anti-IgE antibody currently in early-stage clinical development, designed to deliver faster and more durable suppression of allergic responses. Exl-111 builds on the same biological pathway as Novartis’ blockbuster Xolair but is engineered to improve efficacy, dosing convenience, and overall disease control across multiple IgE-mediated conditions. The transaction is expected to close in the second half of 2026, pending regulatory approvals, further strengthening Novartis’ leadership in immunology and allergy therapeutics. (Link)
  9. PCSI Completes Acquisition of CareStarter and Feedback to Launch PCSIx Innovation Unit PCSI has finalized the acquisition of CareStarter and Feedback, two companies focused on patient engagement and care coordination. These acquisitions serve as the foundation for PCSI’s new innovation unit, PCSIx. The investment aims to bridge the gap between healthcare providers and patients by utilizing CareStarter’s resource platforms and Feedback’s communication tools. By consolidating these technologies, PCSI intends to streamline the patient journey and improve health literacy. This move signals a shift toward integrated, patient-centered care models, with the investor focusing on long-term value through improved patient outcomes and reduced administrative friction in the care delivery process. (Link)
  10. Collectly to Acquire Pledge Health to Accelerate AI Automation in Patient Finance Collectly has announced its acquisition of Pledge Health, a strategic move designed to integrate AI-driven automation into the patient financial experience. The acquisition focuses on streamlining medical billing and transparent pricing, addressing one of the most significant pain points in American healthcare. By combining forces, Collectly and Pledge Health aim to provide patients with clearer financial insights while helping providers increase collection rates through automated workflows. This investment highlights the growing market for fintech solutions within the healthcare sector, where AI is being leveraged to reduce manual errors and improve the overall transparency of healthcare costs. (Link)
  11. Vitality Acquires Ramp Health to Merge AI Behavioral Health and Workplace Safety Vitality has successfully acquired Ramp Health, aiming to create a comprehensive platform that merges AI-powered behavioral health services with workplace safety protocols. This acquisition is part of Vitality’s broader strategy to enhance corporate wellness programs by providing employers with data-driven tools to support employee mental and physical health. The integration of Ramp Health’s expertise allows Vitality to offer more personalized health interventions and preventative safety measures. Investors see this as a timely move, given the increasing corporate focus on employee well-being and the role of AI in delivering scalable health solutions in a professional environment. (Link)
  12. Palm Primary Care Acquires Two Clinics in Azle to Expand Local Access Palm Primary Care has expanded its clinical footprint by acquiring two primary care clinics in Azle, Texas. This investment is part of the company’s localized growth strategy, focusing on increasing access to high-quality primary care in suburban and rural areas. By acquiring established practices, Palm Primary Care can immediately serve an existing patient base while implementing its standardized care models and advanced technology systems. The deal reflects a continuing trend of consolidation in the primary care sector, where larger organizations acquire independent practices to achieve economies of scale and provide more integrated services to the local community. (Link)
  13. HealthDrive Corp Acquires Georgia Long-Term Care Consulting HealthDrive Corp, backed by Cressey & Company, has acquired Georgia Long-Term Care Consulting, expanding its reach into the specialized field of post-acute and long-term care services. This acquisition allows HealthDrive to strengthen its consultancy and on-site clinical service offerings for seniors in long-term care facilities. The investment is driven by growing demand for specialized medical services within the aging population. By integrating the Georgia-based firm, HealthDrive enhances its ability to manage complex care needs and regulatory compliance for long-term care facilities. This move reinforces HealthDrive’s position as a major player in the evolving landscape of senior healthcare services in the United States. (Link)
  14. Cerebral Acquires Inflow to Broaden Mental Health and ADHD Support Cerebral has acquired Inflow, a startup focused on digital tools for ADHD management, to broaden its behavioral health platform. This acquisition enables Cerebral to provide more specialized, non-clinical support for neurodivergent individuals, complementing its existing telepsychiatry services. The investment highlights Cerebral’s strategy to become a holistic provider of mental health solutions by incorporating self-management tools and community support into its clinical model. Investors are watching how this expansion into digital therapeutics will help Cerebral differentiate itself in a crowded telehealth market while improving long-term patient engagement and clinical outcomes for those with ADHD. (Link)
  15. Gilead Sciences to Acquire Ouro Medicines in $2.2B Deal to Expand Autoimmune Pipeline Gilead Sciences announced it will acquire Ouro Medicines in a transaction valued at up to approximately $2.2 billion, including $1.675 billion upfront and potential milestone payments. The deal centers on Ouro’s lead asset, a clinical-stage BCMAxCD3 T-cell engager designed to treat severe autoimmune diseases by targeting pathogenic B cells. Early data has shown promising efficacy and a differentiated safety profile, positioning the therapy as a potential “immune reset” approach. Strategically, the acquisition expands Gilead’s inflammation and immunology pipeline as it seeks to diversify beyond its core HIV franchise. (Link)
  16. RTW Investments Boosts Stake in Cogent Biosciences RTW Investments increased its position in U.S.-based Cogent Biosciences by purchasing over 4.1 million shares, representing an estimated $116 million investment and signaling strong conviction in the company’s pipeline. The stake now accounts for roughly 2.7% of RTW’s reportable assets, highlighting the importance of the position within its biotech-focused portfolio. Cogent is advancing precision therapies for genetically defined diseases, with key U.S. regulatory milestones, including an FDA decision expected in late 2026, acting as major value inflection points. The move reflects continued investor interest in U.S. biotech innovation, particularly companies nearing potential commercialization. (Link)
  17. GeBBS Healthcare Solutions Announces Acquisition of RND OptimizAR GeBBS Healthcare Solutions, Inc., a leading provider of technology-enabled Revenue Cycle Management (RCM) and Risk Adjustment Solutions for healthcare providers and payers, announced this morning the acquisition of RND OptimizAR, an India-based specialized provider of Revenue Cycle Management services focused on the Durable Medical Equipment (DME) and Home Medical Equipment (HME) market. The deal strengthens GeBBS’ capabilities in niche RCM segments. GeBBS is backed by global investors including EQT and ChrysCapital. (Link)
  18. Vision Innovation Partners Acquires Frederick Eye Institute Vision Innovation Partners (VIP), a leading Mid-Atlantic eye care platform with 69 locations and backed by Gryphon Investors, announced this morning the acquisition of Frederick Eye Institute, a comprehensive ophthalmology practice in Frederick, Maryland. This marks VIP’s 28th add-on acquisition since 2017 and further strengthens its presence in the key Maryland. (Link)
  19. AI Maverick Intel Announces LOI to Acquire HEAL Access Canada  The proposed acquisition would integrate HEAL’s AI-powered patient navigation and virtual care coordination platform into its ecosystem. The deal represents the first transaction under its Right of First Refusal agreement with HEAL. (Link)
  20. Monument MicroCap Partners Invests in Champion Wellness Centers to Support Growth and Expansion The investment supports Champion Wellness Centers, a Tampa-based provider of chiropractic and multidisciplinary wellness services. The company operates a network of clinics offering physical therapy, regenerative medicine, and other integrated treatments, positioning it to benefit from growing demand for holistic care. The partnership will support geographic expansion and add-on acquisitions. (Link)

Venture Deals and Other

  1. eMed Raises $200 Million Led by Aon, Including Participation from Tom Brady and Linda Yaccarino to Expand GLP-1 Access eMed has received a strategic investment from a high-profile group including Tom Brady and Linda Yaccarino to support its mission of expanding access to GLP-1 weight-loss medications. The funding will enhance eMed’s digital health platform, which provides clinical oversight and testing for patients seeking metabolic treatments. This investment reflects the massive market demand for weight-loss drugs and the role of telehealth in managing prescription distribution. The involvement of such prominent figures suggests a shift toward celebrity-backed healthcare ventures that aim to combine medical credibility with mass-market consumer appeal in the rapidly growing obesity-treatment sector. (Link)
  2. Adonis Raises $40 Million in Series C Funding to Transform Revenue Cycle Management Adonis has successfully closed a $40 million Series C funding round to accelerate the development of its AI-driven revenue cycle management platform. This significant capital infusion will be used to enhance the company’s automation capabilities, helping healthcare providers reduce administrative burdens and improve billing accuracy. The investment round reflects strong venture capital confidence in Adonis’s ability to solve complex financial inefficiencies within the healthcare system. With this new funding, Adonis plans to expand its engineering team and scale its go-to-market strategies, aiming to become the standard for financial operations in large-scale medical groups and health systems. (Link)
  3. Blossom Health Secures Series A Funding Led by Headline to Expand Telepsychiatry Services Blossom Health has raised a Series A investment round, with Headline serving as the lead investor. The funding is intended to scale Blossom Health’s telehealth and telepsychiatry platform, which focuses on providing accessible mental healthcare to underserved populations. Headline’s involvement brings both capital and strategic expertise in scaling consumer-facing digital health brands. Blossom Health plans to use the funds to hire more clinical staff and enhance its mobile application interface. This deal highlights the continued venture capital appetite for mental health startups that leverage technology to overcome traditional barriers to care, such as cost and geographic location. (Link)
  4. Dimer Health Raises $13.5 Million for AI-Driven Post-Discharge Care Platform Dimer Health has secured $13.5 million in funding to support its AI-driven platform designed to improve post-discharge patient care. The investment will be used to further develop technology that monitors patients after they leave the hospital, aiming to reduce readmission rates and improve recovery outcomes. By utilizing predictive analytics, Dimer Health helps clinicians identify high-risk patients who may need immediate intervention. This venture deal underscores the growing interest in “hospital-at-home” models and the use of artificial intelligence to bridge the gap between acute hospital stays and long-term recovery in a home setting. (Link)
  5. Gimlet Labs Raises $80 Million to Transform AI Inference Infrastructure Gimlet Labs has closed a substantial $80 million funding round aimed at transforming AI inference infrastructure. While not strictly a healthcare firm, its technology is pivotal for the future of AI-driven medical diagnostics and drug discovery. The investment will allow Gimlet Labs to scale its hardware and software solutions that make running complex AI models faster and more cost-effective. Venture capitalists are betting on Gimlet Labs to provide the foundational infrastructure that will power the next generation of AI applications across various sectors. This capital will be used for research and development and expanding their manufacturing capabilities to meet global demand. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Feb 2nd, 2026

LECO_Weekly-Healthcare-News_2-2-2026Download
  1. Boston Scientific (NYSE: BSX) completes $600M acquisition of Nalu Medical to deepen neuromodulation portfolio for chronic pain The deal adds Nalu’s miniaturized, battery‑free implantable pulse generator for spinal cord and peripheral nerve stimulation, wirelessly powered by an external wearable disc and controlled via smartphone, with an expected 18‑year service life. Nalu’s system, cleared initially by the FDA in 2019 and later for whole‑body MRI use, delivers neuromodulation for chronic neuropathic pain with capabilities comparable to larger IPGs. Boston Scientific projects Nalu revenue above $60 million in 2025 with more than 25% growth in 2026 and expects the transaction to become increasingly accretive to earnings after 2027. (Link)
  2. Laborie acquires JADA System for $465M, backed by Patricia Industries to strengthen its global maternal health and postpartum haemorrhage care portfolio The acquisition brings an FDA-cleared device for rapid control of abnormal postpartum uterine bleeding into Laborie’s comprehensive obstetrics portfolio spanning antepartum through neonatal care. JADA uses low-level vacuum to stimulate natural uterine contractions, helping stop postpartum haemorrhage quickly and effectively and has already been used in more than 136,000 mothers across over 20 countries, supported by multiple safety and effectiveness studies. Laborie will onboard over 90 primarily commercial team members as part of a long-term strategy to back innovations that improve maternal outcomes and support sustainable growth. (Link)
  3. Halozyme Therapeutics acquires Surf Bio for up to $400M to expand hyperconcentration capabilities in subcutaneous drug delivery The transaction, closed in late December 2025 and announced January 28, 2026, includes $300M upfront (subject to adjustments) and up to $100M in development/regulatory milestones. Surf Bio’s platform enables high-concentration formulation of monoclonal antibodies, small molecules, and biologics using spray drying, a novel protective excipient, and polymer-based surface tension reduction for protein stability and low-friction delivery via auto-injector. Complementing Halozyme’s Enhanze hyaluronidase and recent Elektrofi/Hypercon acquisition, the technology extends IP into the mid-2040s, opens non-exclusive partnerships across autoimmune, neurology, nephrology, cardiovascular, nucleic acids, and ADCs, and supports rapid home-administration innovations, positioning Halozyme for durable royalty growth and next-generation delivery leadership. (Link)
  4. Illumina (NASD: LMN) acquires SomaLogic and assets from Standard BioTools for $350 million plus milestones to expand proteomics and multiomics leadership The acquisition strengthens Illumina’s position in the fast-growing proteomics market by integrating SomaLogic’s data-driven protein analysis technologies with Illumina’s next-generation sequencing (NGS) and multiomics solutions. Customers will gain access to enhanced tools, including SomaScan assays, DRAGEN software, and Illumina Connected Multiomics, enabling large-scale, flexible, and cost-efficient analysis of complex biological data. The combination supports faster drug discovery and deeper insights into human health. Illumina will maintain continuity for existing SomaLogic customers while expanding global access to the unified platform, investing in scalable growth and innovation across its sequencing and proteomics ecosystems. (Link)
  5. Sword Health acquires Kaia Health in $285M transaction backed by General Catalyst, Khosla Ventures, Transformation Capital and Founders Fund to scale AI-first MSK and pulmonary care in the U.S. and Germany The transaction adds Kaia’s digital musculoskeletal and pulmonary programs and its coveted position in Germany’s reimbursed digital health pathway, giving access to more than 70 million publicly insured individuals. Sword plans to migrate Kaia’s U.S. members to its own AI Care platform, unifying client relationships while extending a wider range of AI-enabled remote services that blend automation with clinician oversight. The combined organization aims use of AI care manager agents to automate administrative tasks and support more accessible virtual care. (Link)
  6. Premise Health acquires Crossover Health, via its financial sponsors OMERS Private Equity, Ares Management, and Ares Capital Corporation BDC creating unified advanced primary and occupational care company The combined organization will operate nearly 900 onsite, nearsite and virtual wellness centers, serving more than 400 employers, unions, tribes and health plans across the U.S. Its integrated model spans advanced primary care, occupational health, behavioral health, care management and navigation, physical therapy and chiropractic, with Premise’s pharmacy services adding chronic condition support and virtual dispensing. Both companies will continue developing alternative payment models, including a primary‑care‑centered health plan, with leadership from both executive teams retained to drive a shared vision of scalable, team‑based primary care that lowers costs and improves outcomes. (Link)
  7. Spring Health to acquire Alma in deal backed by Generation Investment Management, Tiger Global, Thoma Bravo, Cigna Ventures, Optum Ventures, Insight Partners, Tusk Venture Partners, Primary Venture Partners, and Sound Ventures to build AI-enabled lifelong mental health platform and expand nationwide care access The acquisition unites two major digital mental health innovators, combining Spring Health’s AI-driven precision care platform with Alma’s strong national payer relationships and provider infrastructure. The deal will integrate advanced technology, data-informed personalization, and in-network clinician enablement to improve patient outcomes while easing administrative burdens. Both leverage shared resources to advance quality, accessibility, and value across the evolving mental healthcare ecosystem. (Link)
  8. Resonetics to acquire Resolution Medical in a Carlyle, GTCR and Arcline Investment Management–backed deal to expand neuromodulation and structural heart device capabilities The acquisition will add Resolution Medical’s integrated design, engineering and cleanroom manufacturing capabilities for complex Class II and III devices, significantly deepening Resonetics’ presence in neuromodulation, structural heart and interventional cardiology markets. More than 240 employees, including over 100 engineers, will join Resonetics, enabling it to support customers from early product design and NPI through high‑volume production on a larger global footprint. Both organizations emphasize continuity for existing customers while positioning the combined company as a more comprehensive development and manufacturing partner across the full medical device lifecycle. (Link)
  9. Kodiak Solutions acquires BESLER, via its financial sponsor TPG to strengthen revenue recovery and reimbursement capabilities The acquisition brings BESLER’s revenue integrity tools, including Transfer DRG underpayment detection software and managed reimbursement services, onto Kodiak’s existing analytics and automation platform for hospitals and medical practices. Kodiak aims to give health system CFOs deeper, more actionable insight into net revenue, benchmarking, and reimbursement performance while simplifying complex business office workflows. BESLER’s leadership and subject-matter experts, including former CEO Jonathan Besler, are joining Kodiak to help support more than 2,300 hospitals and 350,000 physicians, while founder Philip Besler retires after four decades building the firm. (Link)
  10. Nuwellis (NASD: NUWE) to acquire Rendiatech to expand real-time kidney function monitoring and advance cardiorenal care portfolio The acquisition advances Nuwellis’ move beyond fluid management into continuous renal diagnostics, enhancing its precision cardiorenal care capabilities. Rendiatech’s Clarity™ system provides automated, continuous urine-output monitoring, offering improved accuracy and efficiency over manual methods. The integration of this technology will support earlier kidney stress detection and data-driven clinical decisions in critical care. Nuwellis plans to use its existing commercial and clinical infrastructure to bring Rendiatech’s innovation to market without new sales channels. The transaction, approved by both companies’ boards, marks a key milestone in establishing a more comprehensive cardiorenal platform once customary closing conditions are met. (Link)
  11. Wisp acquires TBD Health to build women-focused national PrEP and sexual health enterprise and hybrid care platform The deal adds a 50‑state sexual health and diagnostics infrastructure, including routine STI/HIV testing, virtual clinical support and deep partnerships with hospital systems and public health organizations. TBD Health’s TelePrEP and diagnostics capabilities, already integrated with partners like Mount Sinai Health System, San Francisco AIDS Foundation and Planned Parenthood Direct, will underpin Wisp’s move beyond direct‑to‑consumer into enterprise and hybrid care models. Together, the companies plan to close major gaps in preventive sexual health—particularly for women—by offering turnkey PrEP and testing solutions that plug into existing clinical workflows and broaden access across consumer, employer and public health channels. (Link)
  12. NOCD acquires Rebound Health, leveraging Noto AI platform to scale virtual OCD and PTSD specialty care The combined organization will expand virtual, evidence-based therapy for OCD and trauma-related disorders nationwide using Noto, an AI-powered infrastructure that supports payer operations, member identification, enrolment, and clinical workflows. NOCD contributes a large, W‑2-employed therapist network delivering more than 1 million OCD sessions annually, supported by tools like AI-assisted notetaking, outcomes tracking, and peer support between visits. Clinical studies of NOCD’s virtual exposure and response prevention model show meaningful symptom reductions for children and teens, while peer interventions increase engagement, and Noto will now also be used to scale Rebound’s PTSD and complex PTSD services across the U.S. (Link)
  13. Premier Radiology Services to acquire National Radiology Solutions (NRAD) to strengthen nationwide teleradiology network and clinical coverage The merger combines two established teleradiology providers to create a stronger national network with enhanced clinical coverage and streamlined operations. By integrating technological infrastructure, administrative systems, and subspecialty expertise, the unified organization will deliver faster, more accurate diagnostic interpretations. NRAD’s team, including founder Robb Kolb, will join the combined company to ensure seamless service for existing clients. The partnership places emphasis on physician autonomy, innovation, and expanding access to high-quality radiology services. Together, the organizations aim to advance patient care standards and improve efficiency for outpatient healthcare providers across the United States. (Link)
  14. Choice Health at Home to acquire Cy-Fair Health Care and Alliant, via its financial sponsor Trive Capital to expand home health and hospice services across key Southwestern markets The acquisition builds on Choice Health at Home’s strategy to enhance integrated home-based care across key Southwestern markets. Both Cy-Fair Health Care in Texas and Alliant in Colorado bring strong clinical reputations and deep community roots, which will now be supported by Choice Health’s broader operational infrastructure and resources. The move strengthens continuity of care for patients and families, with existing staff retained and services uninterrupted. By combining expertise, technology, and compassionate clinical teams, the expanded organization will improve home health and hospice delivery while advancing Choice Health’s mission to provide accessible, patient-centered care across its seven-state network. (Link)
  15. ncgCARE to acquire Broadstep of North Carolina through Carolina Outreach to expand statewide behavioral health services The acquisition broadens ncgCARE’s community-based behavioral health network across eastern and southeastern North Carolina, reinforcing its commitment to accessible, high-quality mental health and substance use care. Broadstep’s existing staff, leadership, and programs will remain in place, ensuring continuity for patients and families. By integrating Broadstep’s operations into Carolina Outreach, ncgCARE will provide expanded operational, clinical, and compliance support to strengthen long-term sustainability and service delivery. The partnership emphasizes stability, quality, and local engagement while enhancing capacity to meet growing behavioral health needs in communities across Gastonia, Lumberton, Jacksonville, Supply, and Wilmington, North Carolina. (Link)

Venture and Other News  

  1. Vaxcyte prices $550M public offering at $50 per share to fund pneumococcal and infectious disease vaccine pipeline The offering includes 11,000,000 shares with a 30-day underwriter option for up to 1,650,000 additional shares, expecting gross proceeds of $550M (before discounts/expenses), closing February 2, 2026. Proceeds will support clinical advancement of lead next-generation pneumococcal conjugate vaccine VAX-31 (Phase 3 adult/Phase 2 infant), VAX-24, plus prophylactic programs for Group A Strep (VAX-A1) and Shigella (VAX-GI). Leveraging its XpressCF cell-free protein synthesis platform for high-fidelity conjugates, Vaxcyte aims to address serious bacterial diseases with broader, more effective immunizations, accelerating late-stage trials, manufacturing scale-up, and progress toward preventing unmet infectious threats. (Link)
  2. Veradermics and Eikon Therapeutics file for IPOs targeting up to $181M and $318M amid biotech market reopening Veradermics (NYSE: MANE) seeks approximately $181M to advance Phase III VDPHL01 (extended-release oral minoxidil) for pattern hair loss in men and women, supporting approval, commercialization, physician education, brand awareness, supply chain, and infrastructure in dermatology. Eikon Therapeutics (Nasdaq: EIKN), led by former Merck executive Roger Perlmutter, targets up to $318M (with overallotment) primarily for clinical progression of TLR7/8 agonists EIK1001 (melanoma) and EIK1003 (non-small cell lung cancer), plus selective PARP1 inhibitors and WRN helicase assets in challenging oncology indications. The January 2026 filings signal renewed investor confidence post-2025 slowdown, enabling late-stage advancement, pipeline expansion, and public-market capitalization for these high-potential biotechs. (Link)
  3. Cellares raises $257M in Series D round led by Eclipse and BlackRock with participation from T. Rowe Price, Gates Frontier, Duquesne Family Office, Intuitive Ventures, DC Global Ventures and DFJ Growth to scale global cell therapy manufacturing The new funding supports Cellares’ global expansion as it prepares for commercial-scale cell therapy production by 2027. The company will build new manufacturing facilities in the Netherlands and Japan, complementing sites in New Jersey and South San Francisco. Its automated “Cell Shuttle” system enables end-to-end cell therapy production, addressing industry bottlenecks through scalable, high-tech infrastructure. With increasing demand and regulatory validation, Cellares is positioning itself as a leading integrated developer and manufacturer supporting global biopharma partners, including Bristol Myers Squibb. The financing advances its mission to industrialize cell therapy and move toward a public listing. (Link)
  4. Tenpoint Therapeutics raises $235M from Janus Henderson, EQT Nexus, Hillhouse, British Business Bank, EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio, Wille, and Hercules Capital to accelerate commercialization of YUVEZZI™ The financing strengthens Tenpoint Therapeutics’ position for the commercial launch of YUVEZZI™, the first FDA-approved dual-agent, once-daily eye drop for presbyopia. The funding includes an $85 million Series B round and a $150 million credit facility, providing the capital needed to scale manufacturing, distribution, and marketing. Tenpoint aims to meet the needs of millions affected by age-related vision decline while delivering a differentiated treatment backed by strong clinical data and safety performance. The company’s leadership is focused on driving YUVEZZI™’s successful rollout and expanding access to innovative ophthalmic solutions. (Link)
  5. Breakthru Medicine emerges from stealth with $60M Series A financing to advance disruptive cancer therapeutics The funding, supported by investors including Dave Morehead (Baylor University endowment), Fred Eshelman (Eshelman Ventures), and Mark Gergen, enables Breakthru Medicine to build its tumor-agnostic platform targeting hard-to-drug cancers through small molecules, next-generation antibody-drug conjugate payloads, and a novel molecular glue approach. The company prioritizes patient-first development by rigorously selecting breakthrough candidates early and eliminating non-viable programs. The capital accelerates pipeline progression and platform expansion to redefine therapeutic possibilities for oncology indications. (Link)
  6. TRexBio raises $50M from Janus Henderson Investors, Alexandria Venture Investments, Avego BioScience Capital, Eli Lilly, Johnson & Johnson Innovation JJDC, Pfizer Ventures and SV Health Investors to advance tissue-targeted Treg immunology pipeline The financing supports TRexBio’s ongoing clinical and preclinical programs focused on tissue-specific regulatory T cell therapies for autoimmune and inflammatory diseases.. Leveraging its Deep Biology Platform, TRexBio maps tissue Treg behavior to uncover novel therapeutic targets. The investment underscores confidence in the company’s precision immunoregulatory approach aimed at delivering more effective, durable treatments for diseases such as atopic dermatitis and other inflammatory disorders. (Link)
  7. Prenosis secures $20M Series A led by PACE Healthcare Capital with UC Investments, UCI Health Ventures, Labcorp Venture Fund, GHIC, Illinois DCEO, and Carle Health, plus $20M BARDA contract to advance AI diagnostics and therapeutics The combined $40 million will drive Prenosis’ development of biology-based, AI-powered diagnostic and therapeutic tools for critical care conditions such as sepsis, ARDS, and acute kidney injury. The BARDA-funded program will include a pivotal clinical trial evaluating an AI-enabled steroid companion diagnostic for severe respiratory infections. These initiatives strengthen Prenosis’ mission to personalize treatment by combining advanced diagnostics with targeted therapeutics, marking a major step in improving outcomes for critically ill patients through precision care. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jan 26th, 2026

LECO_Weekly-Healthcare-News_1-26-2026Download
  1. Winter Storm Fern Cripples Half the Country This Weekend
    • CNBC: $100B expected economic loss and damages from storm (Link) 
    • CNBC: Transportation Sec. Duffy says air travel will return to normal by Wednesday (Link) 
    • The Weather Channel: Winter Storm Fern Turns Deadly In Louisiana, Outages For Hundreds Of Thousands Vulnerable To Ice, Snow (Link) 
    • National Public Radio: As the winter storm rages, here’s what to know in your state(Link)
  2. GSK (NYSE:GSK) pays $2.2B to acquire Rapt Therapeutics (NASD:RAPT) and Food Allergy Antibody Ozureprubart GSK is acquiring Rapt Therapeutics for $58 per share, gaining global (ex‑China) rights to ozureprubart, an extended‑half‑life anti‑IgE antibody being studied as a 12‑weekly prophylactic treatment for food allergies. Unlike currently approved IgE inhibitors that require injections every 2–4 weeks, ozureprubart aims to offer sustained protection with less frequent dosing while targeting the same validated pathway as Xolair. The deal follows Rapt’s strategic pivot away from its CCR4 inhibitor program after clinical setbacks and positions ozureprubart for phase 2 readout in 2027 and a planned phase 3 program, backed by GSK’s global development and commercialization infrastructure. (Link)
  3. BioCryst (NASD: BCRX) acquires Astria Therapeutics (NASD:ATXS) in $700M deal to Build Comprehensive Hereditary Angioedema Treatment Platform The transaction adds Navenibart, a long-acting plasma kallikrein inhibitor in Phase 3, which is being developed as a prophylactic HAE treatment with every‑three or every‑six month dosing to improve patient convenience and attack control. BioCryst now pairs its existing oral therapy ORLADEYO with a potential injectable option to give clinicians more flexibility in tailoring care. The deal also brings STAR0310, an early atopic dermatitis program for which strategic options will be explored, and augments BioCryst’s leadership with Astria’s former CEO joining the board and a senior development leader taking charge of technical operations. (Link)
  4. Georgia ProtonCare Center, Inc. Files Chapter 11 to Facilitate Competitive Sale Process and Enters Into Asset Purchase Agreement With Emory Healthcare Georgia ProtonCare Center (GPCC), owner of Georgia’s only proton therapy cancer treatment facility in Midtown Atlanta, has filed for Chapter 11 bankruptcy to facilitate a court-supervised sale process and ensure uninterrupted patient care. The company has signed an asset purchase agreement with Emory Healthcare (via Emory University Hospital Midtown) as the stalking horse bidder to acquire substantially all assets, with Emory clinicians already providing daily treatment at the center. GPCC aims to complete the competitive sale by Q2 2026, prioritizing seamless continuation of precision proton therapy services for cancer patients while operations continue as usual under court-approved funding. (Link)
  5. KidsChoice Announces Majority Investment from Aquitaine Capital to Support Growth and Clinical Excellence KidsChoice, an Oklahoma-based provider of clinic-centered autism and pediatric therapy services including ABA, speech, and occupational therapy, has secured a majority investment from women-owned private equity firm Aquitaine Capital to fuel expansion, enhance clinical excellence, and strengthen infrastructure. The partnership supports thoughtful growth through new clinic openings, strategic M&A, and complementary offerings while prioritizing individualized, outcomes-driven care for children and families. (Link)
  6. Community Health Systems Sells Crestwood Medical Center to Huntsville Hospital Health System in $450M Deal The transaction will transfer Crestwood Medical Center, a 180‑bed acute care hospital in Huntsville, Alabama, along with a freestanding emergency department in Harvest and multiple clinics and outpatient assets, to a regional nonprofit operator. Crestwood’s roughly 1,000 employees will continue normal operations with no planned changes to services or medical staff privileges during the transition. Huntsville Hospital Health System, already a major 14‑hospital network across northern Alabama and southern Tennessee, views the deal as a way to better coordinate local care as Huntsville’s population rapidly grows, while the seller continues its strategy of divesting assets to strengthen its financial position. (Link)
  7. BioStem Technologies (OTC: BSEM) and BioTissue sign Up to $40M Surgical and Wound Care Asset DealThe transaction adds BioTissue’s Neox and Clarix placental- and umbilical‑tissue allograft product lines, along with a national direct and independent sales force and key group purchasing organization contracts, giving BioStem an immediate presence in hospital inpatient and outpatient settings. The acquired surgical and wound care assets, which generated about $29 million in 2025 sales, broaden BioStem’s chronic and acute wound care portfolio and create entry into high‑value segments such as burns and soft‑tissue repair. Deal terms include an upfront $15 million cash payment plus up to $25 million in potential regulatory and commercial milestone payments. (Link)
  8. Harmony Healthcare IT acquires Blue Elm, via its financial sponsor Novacap to build Comprehensive MEDITECH Data Lifecycle Platform Harmony Healthcare IT has acquired Blue Elm to offer MEDITECH hospitals a single, end-to-end partner for data extraction, conversion, migration, archiving, optimization, and real-time access across all MEDITECH versions. The combined capabilities help hospitals retire costly legacy systems, strengthen data integrity, and improve accessibility as they upgrade or transition EHR platforms. By unifying services under one organization and relying on U.S.-based resources instead of offshore outsourcing, the company aims to shorten complex project timelines, enhance security and quality, and better support hospitals under pressure to improve care quality while reducing operating costs. (Link)
  9. PhaseWell Research acquires Bio Behavioral Health Partner, via its financial sponsor Shore Capital Partners to expand Community-Based Neuropsychiatric Clinical Trials The acquisition will strengthen PhaseWell’s national network of community clinical research sites focused on neurologic and psychiatric disorders. The collaboration aims to broaden patient access to neuropsychiatric trials by leveraging BBH’s experience in community-based studies and PhaseWell’s nationwide platform and infrastructure. Together, the organizations plan to support sponsors with reliable patient enrolment, strong operational execution, and high-quality data while advancing next-generation CNS therapeutics across complex therapeutic areas, including oncology, cardiovascular/metabolic conditions, and dermatology. (Link)
  10. Pair Team acquires Town Square to Advance AI-Enabled Community Care for Medicare and Medicaid Beneficiaries The acquisition combines an AI-driven medical group with a social care coordination platform to better integrate clinical, behavioral, and social services for underserved populations. Technology will orchestrate complex, cross-setting care tasks so human teams can concentrate on clinical decisions, hands-on support, and relationships with patients and local organizations. Town Square’s founder will lead network expansion and community partnerships within the new structure, which emphasizes responsible AI, robust outcomes measurement, and investment in community-based infrastructure to extend whole-person care to people historically excluded from the healthcare system. (Link)
  11. Aspen Surgical expands Infection Prevention Portfolio with acquisition of Ruhof Healthcare, via its financial sponsors Linden and Audax Private Equity The buyer is adding enzymatic detergents, cleaning verification tools, and automated and manual instrument and endoscope reprocessing solutions to deepen its presence in operating rooms, sterile processing, and endoscopy settings. Ruhof’s portfolio, including Endozime detergents, ScopeValet single-use consumables, CleanRead ATP contamination monitoring, and instrument refurbishment services, will bolster the SPD360 Performance Solutions platform and complement existing brands such as Symmetry, Bookwalter, and Precept. The transaction covers all Ruhof operations, brands, and product lines, with integration set to begin immediately and no near-term disruption expected for customers, suppliers, or employees. (Link)
  12. TridentCare acquires DispatchHealth Imaging Unit to Grow National Portable Diagnostics Network The acquisition adds a multistate mobile X‑ray and ultrasound operation that serves patients at home, in post‑acute facilities, and in correctional settings, expanding TridentCare’s reach and capacity. By integrating these imaging teams and customers into its national infrastructure, TridentCare aims to speed response times, improve scheduling flexibility, and deliver more consistent service quality for clinicians and patients. DispatchHealth will continue focusing on providing complex care in the home and will coordinate imaging through technology and partnerships so patients and providers experience seamless, integrated services. (Link)
  13. Morris & Dickson Completes Transaction to Acquire Prodigy Health Morris & Dickson (M&D), the nation’s largest independent wholesale and specialty pharmaceutical distributor, has completed its acquisition of Prodigy Health, a specialty pharmaceutical distribution and services company focused on plasma-derived therapies. The transaction expands M&D’s specialty portfolio, broadens access to plasma therapies for hospitals, clinics, infusion centers, and alternative care sites nationwide, and strengthens its independent platform for manufacturers through a compliance-first approach. (Link)
  14. Main Post Partners and HomeWell Leadership acquire HomeWell Franchising to Accelerate Senior In‑Home Care Growth The deal pairs a national non‑medical home care franchisor with a private equity firm experienced in franchising and consumer service brands, aiming to fuel the next phase of expansion. The partners emphasize a “partnership, not ownership” philosophy, focusing on close collaboration with franchisees and caregivers to scale services while preserving mission and culture. Building on several years of rapid revenue growth and record franchise development, the company plans to invest in tools, resources, and support that help local agencies grow and better serve seniors and homebound individuals in their communities. (Link)

Venture and Other News  

  1. Zarminali Paediatrics raises $110M in Series A funding led by Healthier Capital, with participation from General Catalyst, K2 HealthVentures, and Boston Children’s Hospital to expand integrated paediatric care footprint The company will use the new capital to scale its proprietary tech platform, enter additional states and open de novo clinics while continuing to acquire established paediatric groups. Its model centers on a single branded multispecialty practice that co-locates clinics with urgent care, directly employing both paediatricians and specialists to coordinate care across the full continuum outside the hospital. Since launching in 2024, Zarminali has rapidly expanded to 28 clinics in eight states and plans at least 15 new sites in 2026, while laying groundwork for future value-based arrangements and building analytics to track clinician performance and patient outcomes. (Link)
  2. Mendra launches with $82M Series A co-led by OrbiMed, 8VC, and 5AM Ventures, with participation from Lux Capital and Wing VC to advance AI-driven rare disease therapeutics Mendra will use the oversubscribed financing to acquire and develop an initial portfolio of high-potential rare disease assets while applying AI to speed patient identification, trial enrollment and global market access. The company is built to modernize how rare disease medicines are developed and commercialized so they reach underserved patients more efficiently worldwide. A veteran leadership team with deep experience in rare disease drug development, global commercialization and AI—drawn from organizations such as BioMarin, Modis Therapeutics, Escient Pharmaceuticals, Palantir and Bayer—will guide strategy across asset selection, clinical execution and business development. (Link)
  3. AnswersNow raises $40M in Series B funding led by HealthQuest Capital, with participation from Left Lane Capital and Owl Ventures to Scale AI-Enabled Virtual Autism Therapy The company will use the new capital to expand its platform, double clinical headcount, add senior leaders and launch new service lines to meet surging demand for autism support. Its AI-driven model pairs families across the U.S. with Master’s- and PhD-level BCBAs for targeted, parent-mediated virtual ABA, cutting weekly therapy time from 30+ hours to about 4–5 while sustaining strong clinical gains. Outcomes data show high family-reported improvements, substantial cost savings for payors and a consistently strong satisfaction score, with forthcoming research in 2026 intended to further validate clinical and economic impact. (Link)
  4. BrightInsight secures $13M investment from Eclipse, General Catalyst, Insight Partners, Mayo Clinic and New Leaf Venture Partners to scale its AI-enabled medication adherence platform The company will deploy the capital to expand its AI-enabled persistence and adherence solutions, including a co-developed Patient App used across multiple diseases and therapies worldwide. By leveraging real-world data and advanced analytics, the platform targets chronically low adherence rates, aiming to predict churn and trigger personalized interventions that keep patients on therapy. BrightInsight reports strong patient engagement and one-year retention across programs and plans to deepen its product roadmap, broaden disease and biopharma partnerships, and add support for caregivers and nurse educators to ease pressure on health systems. (Link)
  5. McKinsey & Co Released their Annual Healthcare Outlook Report. To remain competitive in 2026 and beyond, healthcare leaders must improve performance, embrace technology and rethink traditional care models (Link)
  6. IPO Watchlist
    • Once Upon a Farm — Organic children’s food company co-founded by Jennifer Garner, is targeting a valuation of up to $764.4 million in its upcoming U.S. IPO on the NYSE under the ticker OFRM. (Link)
    • Kallyope — New York City-based biotechnology company specializing in novel therapeutics targeting the gut-brain axis and neural circuits.
    • Kardium — Vancouver area based medical device company focused on cardiac electrophysiology solutions; develops advanced catheter-based systems for the diagnosis and minimally invasive treatment of atrial fibrillation.
    • Tenpoint Therapeutics — London, UK-headquartered (with U.S. operations in Seattle and Irvine) ophthalmic biotechnology company dedicated to age-related vision restoration therapies.
    • Vensure Employer Solutions — Chandler, AZ -based professional employer organization (PEO) and provider of human capital management (HCM) technology serving the healthcare and broader employer ecosystem.